text
stringlengths 102
112k
| url
stringlengths 37
240
| crawl_date
timestamp[us, tz=UTC]date 2024-01-04 00:15:18
2024-01-31 23:10:45
| exclusion_reason
stringclasses 1
value |
|---|---|---|---|
Investors are always looking for stocks that are poised to beat at earnings season and QUALCOMM Incorporated (QCOM - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because QUALCOMM is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for QCOM in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $2.46 per share for QCOM, compared to a broader Zacks Consensus Estimate of $2.38 per share. This suggests that analysts have very recently bumped up their estimates for QCOM, giving the stock a Zacks Earnings ESP of +3.45% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that QCOM has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for QUALCOMM, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2217735/why-qualcomm-qcom-might-surprise-this-earnings-season
| 2024-01-30T23:39:28Z
|
blocked_url
|
ManpowerGroup (MAN - Free Report) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 19.83%. A quarter ago, it was expected that this staffing company would post earnings of $1.34 per share when it actually produced earnings of $1.38, delivering a surprise of 2.99%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Manpower
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Manpower shares have lost about 3.7% since the beginning of the year versus the S&P 500's gain of 3.3%.
What's Next for Manpower?
While Manpower has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Manpower: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.04 on $4.41 billion in revenues for the coming quarter and $5.73 on $18.41 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Staffing Firms is currently in the bottom 18% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, DLH Holdings Corp. (DLHC - Free Report) , has yet to report results for the quarter ended December 2023. The results are expected to be released on January 31.
This company is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents a year-over-year change of -52%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
DLH Holdings Corp.'s revenues are expected to be $101 million, up 38.9% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2217743/manpowergroup-man-beats-q4-earnings-and-revenue-estimates
| 2024-01-30T23:39:34Z
|
blocked_url
|
HCA Healthcare (HCA - Free Report) came out with quarterly earnings of $5.90 per share, beating the Zacks Consensus Estimate of $5.05 per share. This compares to earnings of $4.64 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.83%. A quarter ago, it was expected that this hospital operator would post earnings of $3.97 per share when it actually produced earnings of $3.91, delivering a surprise of -1.51%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
HCA
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
HCA shares have added about 5.9% since the beginning of the year versus the S&P 500's gain of 3.3%.
What's Next for HCA?
While HCA has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for HCA: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $4.76 on $16.53 billion in revenues for the coming quarter and $19.54 on $67.57 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the top 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Tenet Healthcare (THC - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2023. The results are expected to be released on February 8.
This hospital operator is expected to post quarterly earnings of $1.55 per share in its upcoming report, which represents a year-over-year change of -20.9%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level.
Tenet Healthcare's revenues are expected to be $5.25 billion, up 5.2% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2217744/hca-healthcare-hca-beats-q4-earnings-and-revenue-estimates
| 2024-01-30T23:39:41Z
|
blocked_url
|
Allegiant Travel Company (ALGT - Free Report) recently reported a disappointing year-over-year decrease in traffic and capacity for December 2023.
Scheduled traffic (measured in revenue passenger miles) fell 6.8% from December 2022 levels. Capacity (measured in available seat miles) for scheduled service declined 4.4% from the December 2022 reading. The load factor (percentage of seats filled by passengers) in December 2023 reached 82.5%.
Total departures (scheduled services) dipped 5% year over year in December 2023. However, its average stage length (miles) inched up 0.2%. For the total system (including scheduled service and fixed fee contract), Allegiant carried 6.3% less passengers in December 2023 from the year-ago levels. System-wide capacity contracted 3.7% in December on a year-over-year basis.
Fuel price per gallon in December is estimated to be $2.96. For 2023, the guidance for average fuel cost per gallon is $3.09, higher than the prior view of $3.12.
Zacks Rank & Key Picks
ALGT currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the Zacks Transportation sector are Air Canada (ACDVF - Free Report) and Westinghouse Air Brake Technologies Corporation, operating as Wabtec Corporation (WAB - Free Report) .
Air Canada currently sports a Zacks Rank #1 (Strong Buy). An uptick in passenger traffic is aiding ACDVF. Recently, management announced plans to launch a year-round route between Montreal and Madrid. You can see the complete list of today’s Zacks #1 Rank stocks here.
The service will commence in May 2024 as part of its expanded international summer 2024 flying schedule to cater to increased demand.
Wabtec has an expected earnings growth rate of 22.43% for the current year. WAB delivered a trailing four-quarter earnings surprise of 7.11%, on average.
Wabtec presently flaunts a Zacks Rank of 1.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Allegiant Travel Company (ALGT) - free report >>
Westinghouse Air Brake Technologies Corporation (WAB) - free report >>
|
https://www.zacks.com/stock/news/2217746/allegiant-algt-december-traffic-falls-from-year-ago-levels
| 2024-01-30T23:39:47Z
|
blocked_url
|
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
Vericel Corporation (VCEL - Free Report) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. VCEL is quite a good fit in this regard, gaining 23.3% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 25.1% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, VCEL is currently trading at 99.8% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in VCEL may not reverse anytime soon.
In addition to VCEL, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2217749/recent-price-trend-in-vericel-corporation-vcel-is-your-friend-heres-why
| 2024-01-30T23:39:53Z
|
blocked_url
|
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
OSI Systems (OSIS - Free Report) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. OSIS is quite a good fit in this regard, gaining 19.5% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 1% over the past four weeks ensures that the trend is still in place for the stock of this airport security and full-body scanner manufacturer.
Moreover, OSIS is currently trading at 80.9% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in OSIS may not reverse anytime soon.
In addition to OSIS, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2217750/recent-price-trend-in-osi-osis-is-your-friend-heres-why
| 2024-01-30T23:39:59Z
|
blocked_url
|
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.
Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.
The Zacks Earnings ESP, Explained
The Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.
Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.
In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.
Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.
Should You Consider Xylem?
The final step today is to look at a stock that meets our ESP qualifications. Xylem (XYL - Free Report) earns a #3 (Hold) seven days from its next quarterly earnings release on February 6, 2024, and its Most Accurate Estimate comes in at $0.97 a share.
By taking the percentage difference between the $0.97 Most Accurate Estimate and the $0.96 Zacks Consensus Estimate, Xylem has an Earnings ESP of +1.4%. Investors should also know that XYL is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
XYL is just one of a large group of Industrial Products stocks with a positive ESP figure. Parker-Hannifin (PH - Free Report) is another qualifying stock you may want to consider.
Parker-Hannifin is a Zacks Rank #2 (Buy) stock, and is getting ready to report earnings on February 1, 2024. PH's Most Accurate Estimate sits at $5.27 a share two days from its next earnings release.
Parker-Hannifin's Earnings ESP figure currently stands at +0.58% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $5.24.
XYL and PH's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
|
https://www.zacks.com/stock/news/2217752/want-better-returns-dont-ignore-these-2-industrial-products-stocks-set-to-beat-earnings?-don
| 2024-01-30T23:40:00Z
|
blocked_url
|
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
Lakeland Industries (LAKE - Free Report) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. LAKE is quite a good fit in this regard, gaining 27.2% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 1% over the past four weeks ensures that the trend is still in place for the stock of this safety garments manufacturer.
Moreover, LAKE is currently trading at 89.7% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in LAKE may not reverse anytime soon.
In addition to LAKE, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2217753/lakeland-industries-lake-is-on-the-move-heres-why-the-trend-could-be-sustainable
| 2024-01-30T23:40:06Z
|
blocked_url
|
Africa and Latin America are likely to drive a global resurgence in high-impact exploration drilling activity this year to the highest levels seen for at least the last decade, according to market analysis from Rystad Energy.
The consultancy has identified 36 potential high-impact wells to be drilled or spudded in 2024, the highest annual total since it started tracking the market in 2015.
|
https://www.upstreamonline.com/exploration/best-in-decade-banner-year-projected-for-high-impact-exploration-wells/2-1-1590724
| 2024-01-30T23:40:12Z
|
blocked_url
|
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.
Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen and UniCredit S.p.A. Unsponsored ADR (UNCRY - Free Report) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. UNCRY is quite a good fit in this regard, gaining 15.2% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 6% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, UNCRY is currently trading at 96.1% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in UNCRY may not reverse anytime soon.
In addition to UNCRY, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2217754/heres-what-could-help-unicredit-spa-unsponsored-adr-uncry-maintain-its-recent-price-strength
| 2024-01-30T23:40:12Z
|
blocked_url
|
Saudi Aramco’s $10 billion-plus expansion investment at Safaniyah, the world’s largest offshore oilfield, is likely to be deferred or face potential execution delays following the decision by the state behemoth to halt its plans to expand the country’s oil production capacity.
The Saudi state player said on Tuesday that it has received a directive from the Ministry of Energy to maintain its maximum sustainable capacity (MSC) at 12 million barrels per day and not to continue increasing MSC to 13 million bpd.
|
https://www.upstreamonline.com/field-development/clouds-gather-over-10-billion-expansion-on-world-s-largest-offshore-oilfield/2-1-1590634
| 2024-01-30T23:40:18Z
|
blocked_url
|
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen and Adma Biologics (ADMA - Free Report) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. ADMA is quite a good fit in this regard, gaining 46.8% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 17.9% over the past four weeks ensures that the trend is still in place for the stock of this infectious disease drug developer.
Moreover, ADMA is currently trading at 99.2% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in ADMA may not reverse anytime soon.
In addition to ADMA, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2217755/adma-biologics-adma-is-on-the-move-heres-why-the-trend-could-be-sustainable
| 2024-01-30T23:40:19Z
|
blocked_url
|
Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.
We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.
The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.
The Zacks Earnings ESP, Explained
The Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.
With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.
In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.
Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.
Should You Consider NNN REIT?
The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. NNN REIT (NNN - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.83 a share nine days away from its upcoming earnings release on February 8, 2024.
NNN REIT's Earnings ESP sits at +1.02%, which, as explained above, is calculated by taking the percentage difference between the $0.83 Most Accurate Estimate and the Zacks Consensus Estimate of $0.82. NNN is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
NNN is one of just a large database of Finance stocks with positive ESPs. Another solid-looking stock is American Express (AXP - Free Report) .
American Express is a Zacks Rank #2 (Buy) stock, and is getting ready to report earnings on April 18, 2024. AXP's Most Accurate Estimate sits at $3.02 a share 79 days from its next earnings release.
For American Express, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $2.99 is +1.24%.
Because both stocks hold a positive Earnings ESP, NNN and AXP could potentially post earnings beats in their next reports.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
|
https://www.zacks.com/stock/news/2217756/these-2-finance-stocks-could-beat-earnings-why-they-should-be-on-your-radar
| 2024-01-30T23:40:20Z
|
blocked_url
|
London-listed Wood has won $850 million worth of contracts in the Middle East in the last 12 months, securing backlog in Iraq, Saudi Arabia, Qatar and the United Arab Emirates, employing more than 700 new workers, with recruitment underway for 500 new roles.
In a statement issued on Tuesday, the company said one of its most “notable” contract wins was to develop a carbon dioxide transport and storage network that will increase the current global capacity of CO2 storage by some 25%, as well as feasibility studies and preliminary front end engineering design for CCS and low carbon hydrogen projects.
|
https://www.upstreamonline.com/field-development/wood-wins-850-million-of-middle-east-orders/2-1-1590677
| 2024-01-30T23:40:25Z
|
blocked_url
|
Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure helps cut through all the noise.
Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.
Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.
The Zacks Earnings ESP, Explained
The Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.
Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.
Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.
Stocks with a #3 (Hold) ranking, which is most stocks covered at 60%, are expected to perform in-line with the broader market. But stocks that fall into the #2 (Buy) and #1 (Strong Buy) ranking, or the top 15% and top 5% of stocks, respectively, should outperform the market. Strong Buy stocks should outperform more than any other rank.
Should You Consider Scorpio Tankers?
The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Scorpio Tankers (STNG - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $2.78 a share 16 days away from its upcoming earnings release on February 15, 2024.
By taking the percentage difference between the $2.78 Most Accurate Estimate and the $2.68 Zacks Consensus Estimate, Scorpio Tankers has an Earnings ESP of +3.87%. Investors should also know that STNG is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
STNG is just one of a large group of Transportation stocks with a positive ESP figure. Delta Air Lines (DAL - Free Report) is another qualifying stock you may want to consider.
Delta Air Lines, which is readying to report earnings on April 11, 2024, sits at a Zacks Rank #3 (Hold) right now. It's Most Accurate Estimate is currently $0.36 a share, and DAL is 72 days out from its next earnings report.
For Delta Air Lines, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.35 is +3.93%.
STNG and DAL's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
|
https://www.zacks.com/stock/news/2217757/want-better-returns-dont-ignore-these-2-transportation-stocks-set-to-beat-earnings?-don
| 2024-01-30T23:40:26Z
|
blocked_url
|
Australia’s oil and gas industry has backed growing moves across the nation to cut taxpayer funding to an activist group following a scathing assessment of its conduct by the Federal Court.
Australian Energy Producers (formerly APPEA) on Tuesday said it was “ridiculous” for federal or state taxpayers to fund the Environmental Defenders Office (EDO) after its recent unprofessional behaviour was exposed.
Rejecting its case against the Santos-operated Barossa gas project, the Federal Court found that EDO’s evidence and claims were “confection” or “construction” and were “so lacking in integrity that no weight can be placed on them”.
The Australian government is funding the EDO under a four-year grant for A$2 million (US$1.32 million) annually from 2023 to 2026.
Australian Energy Producers chief executive Samantha McCulloch said the Federal Coalition’s pledge on Tuesday to cut EDO funding if it won the next election was in the public interest.
“The taxpayer-funded environmental lawfare must end. Taxpayers have been effectively bankrolling a group that uses the courts to delay energy supplies that are urgently needed both here in Australia and in our region to support energy security and the transition to net zero,” said McCulloch.
She added that Australia’s economic and energy security cannot be held hostage by “such irresponsible actors”.
“The EDO receives millions of dollars of international funding to delay and disrupt projects that are in Australia’s national interest. It is inconceivable that Australian governments would give them a further helping hand to damage our economy.”
Australia’s Northern Territory Labor government this week also pledged to review its A$100,000 annual funding to the EDO in the wake of the court decision.
The Western Australian Liberals have also promised to cease state funding of the EDO — worth A$150,000 this year — if the party wins the next election.
|
https://www.upstreamonline.com/finance/australia-s-oil-and-gas-industry-backs-edo-funding-cuts-after-court-shaming/2-1-1590408
| 2024-01-30T23:40:31Z
|
blocked_url
|
Commvault Systems (CVLT - Free Report) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 6.85%. A quarter ago, it was expected that this data-management software company would post earnings of $0.65 per share when it actually produced earnings of $0.70, delivering a surprise of 7.69%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Commvault
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Commvault shares have added about 2.1% since the beginning of the year versus the S&P 500's gain of 3.3%.
What's Next for Commvault?
While Commvault has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Commvault: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.75 on $210.5 million in revenues for the coming quarter and $2.89 on $817.9 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computer - Software is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, SS&C Technologies (SSNC - Free Report) , is yet to report results for the quarter ended December 2023. The results are expected to be released on February 13.
This financial services software maker is expected to post quarterly earnings of $1.24 per share in its upcoming report, which represents a year-over-year change of +6.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
SS&C Technologies' revenues are expected to be $1.39 billion, up 3.7% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2217762/commvault-systems-cvlt-tops-q3-earnings-and-revenue-estimates
| 2024-01-30T23:40:33Z
|
blocked_url
|
Shares in the major US oilfield service contractors plunged at the start of trading in New York on Tuesday, as investors reacted to news that Saudi Aramco has temporarily pulled the plug on a huge oil production capacity expansion plan, raising questions about future oil demand.
Weatherford International was hardest hit, with more than $1 billion wiped off its market capitalisation as it shares plunged by 16.19%
|
https://www.upstreamonline.com/finance/saudi-move-wipes-1-billion-off-weatherford-value-as-oilfield-service-players-shares-plunge/2-1-1590961
| 2024-01-30T23:40:38Z
|
blocked_url
|
CVS Health (CVS - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugstore chain and pharmacy benefits manager have returned -6.9%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Retail - Pharmacies and Drug Stores industry, which CVS Health falls in, has lost 7.5%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, CVS Health is expected to post earnings of $1.99 per share, indicating no change from the year-ago quarter. The Zacks Consensus Estimate has changed -0.5% over the last 30 days.
The consensus earnings estimate of $8.61 for the current fiscal year indicates a year-over-year change of -0.9%. This estimate has changed +0.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $8.53 indicates a change of -0.9% from what CVS Health is expected to report a year ago. Over the past month, the estimate has changed -0.1%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CVS Health is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For CVS Health, the consensus sales estimate for the current quarter of $90.46 billion indicates a year-over-year change of +7.9%. For the current and next fiscal years, $354.3 billion and $365.75 billion estimates indicate +9.9% and +3.2% changes, respectively.
Last Reported Results and Surprise History
CVS Health reported revenues of $89.76 billion in the last reported quarter, representing a year-over-year change of +10.6%. EPS of $2.21 for the same period compares with $2.09 a year ago.
Compared to the Zacks Consensus Estimate of $88.2 billion, the reported revenues represent a surprise of +1.78%. The EPS surprise was +3.76%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
CVS Health is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CVS Health. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217770/here-is-what-to-know-beyond-why-cvs-health-corporation-cvs-is-a-trending-stock
| 2024-01-30T23:40:39Z
|
blocked_url
|
Fortinet (FTNT - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this network security company have returned +13.5% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Internet - Software industry, to which Fortinet belongs, has gained 8.2% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Fortinet is expected to post earnings of $0.43 per share for the current quarter, representing a year-over-year change of -2.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.3%.
The consensus earnings estimate of $1.56 for the current fiscal year indicates a year-over-year change of +31.1%. This estimate has changed -1.7% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $1.64 indicates a change of +4.8% from what Fortinet is expected to report a year ago. Over the past month, the estimate has changed -1.3%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Fortinet is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Fortinet, the consensus sales estimate for the current quarter of $1.41 billion indicates a year-over-year change of +9.9%. For the current and next fiscal years, $5.3 billion and $5.9 billion estimates indicate +20% and +11.3% changes, respectively.
Last Reported Results and Surprise History
Fortinet reported revenues of $1.33 billion in the last reported quarter, representing a year-over-year change of +16.1%. EPS of $0.41 for the same period compares with $0.33 a year ago.
Compared to the Zacks Consensus Estimate of $1.35 billion, the reported revenues represent a surprise of -1%. The EPS surprise was +10.81%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates just once over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Fortinet is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Fortinet. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217771/fortinet-inc-ftnt-is-a-trending-stock-facts-to-know-before-betting-on-it
| 2024-01-30T23:40:41Z
|
blocked_url
|
Argentina’s state-controlled energy company YPF has approached the market to assess the availability of floating storage and regasification units to deploy at its Escobar liquefied natural gas terminal in the Buenos Aires province.
YPF issued a request for information (RFI) to “gather in-depth knowledge of FSRU and regasification services with an estimate of their corresponding costs,” said the company in a two-page document.
|
https://www.upstreamonline.com/lng/argentina-seeks-floater-for-lng-regasification-terminal/2-1-1590815
| 2024-01-30T23:40:44Z
|
blocked_url
|
Celsius Holdings Inc. (CELH - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this company have returned -4.5% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Food - Miscellaneous industry, to which Celsius Holdings Inc. belongs, has gained 1.4% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Celsius Holdings Inc. is expected to post earnings of $0.16 per share for the current quarter, representing a year-over-year change of +1,500%. Over the last 30 days, the Zacks Consensus Estimate has changed -3.3%.
The consensus earnings estimate of $0.75 for the current fiscal year indicates a year-over-year change of +185.2%. This estimate has changed -1.6% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.95 indicates a change of +26.5% from what Celsius Holdings Inc. is expected to report a year ago. Over the past month, the estimate has changed -1.6%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Celsius Holdings Inc. is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Celsius Holdings Inc. the consensus sales estimate for the current quarter of $323.96 million indicates a year-over-year change of +82%. For the current and next fiscal years, $1.3 billion and $1.8 billion estimates indicate +98.2% and +39.1% changes, respectively.
Last Reported Results and Surprise History
Celsius Holdings Inc. reported revenues of $384.76 million in the last reported quarter, representing a year-over-year change of +104.4%. EPS of $0.30 for the same period compares with -$0.24 a year ago.
Compared to the Zacks Consensus Estimate of $348.35 million, the reported revenues represent a surprise of +10.45%. The EPS surprise was +81.63%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Celsius Holdings Inc. is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Celsius Holdings Inc. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217772/celsius-holdings-inc-celh-is-attracting-investor-attention-here-is-what-you-should-know
| 2024-01-30T23:40:47Z
|
blocked_url
|
Netflix (NFLX - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this internet video service have returned +18.3% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Broadcast Radio and Television industry, to which Netflix belongs, has gained 12.5% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Netflix is expected to post earnings of $4.41 per share for the current quarter, representing a year-over-year change of +53.1%. Over the last 30 days, the Zacks Consensus Estimate has changed +12.7%.
The consensus earnings estimate of $16.93 for the current fiscal year indicates a year-over-year change of +40.7%. This estimate has changed +5.9% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $20.63 indicates a change of +21.8% from what Netflix is expected to report a year ago. Over the past month, the estimate has changed +7.5%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Netflix is rated Zacks Rank #1 (Strong Buy).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Netflix, the consensus sales estimate for the current quarter of $9.25 billion indicates a year-over-year change of +13.4%. For the current and next fiscal years, $38.54 billion and $43.04 billion estimates indicate +14.3% and +11.7% changes, respectively.
Last Reported Results and Surprise History
Netflix reported revenues of $8.83 billion in the last reported quarter, representing a year-over-year change of +12.5%. EPS of $2.11 for the same period compares with $0.12 a year ago.
Compared to the Zacks Consensus Estimate of $8.72 billion, the reported revenues represent a surprise of +1.33%. The EPS surprise was -4.09%.
Over the last four quarters, Netflix surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Netflix is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Netflix. However, its Zacks Rank #1 does suggest that it may outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217773/here-is-what-to-know-beyond-why-netflix-inc-nflx-is-a-trending-stock
| 2024-01-30T23:40:53Z
|
blocked_url
|
Diversified Healthcare (DHC - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this residential care real estate investment trust have returned -17.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks REIT and Equity Trust - Other industry, to which Diversified Healthcare belongs, has lost 3.6% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Diversified Healthcare is expected to post earnings of $0.05 per share for the current quarter, representing a year-over-year change of +66.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -77.8%.
The consensus earnings estimate of $0.19 for the current fiscal year indicates a year-over-year change of +218.8%. This estimate has changed -54.4% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.18 indicates a change of -5.3% from what Diversified Healthcare is expected to report a year ago. Over the past month, the estimate has changed -54.4%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Diversified Healthcare.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Diversified Healthcare, the consensus sales estimate for the current quarter of $362.28 million indicates a year-over-year change of +7.5%. For the current and next fiscal years, $1.41 billion and $1.51 billion estimates indicate +9.9% and +7.2% changes, respectively.
Last Reported Results and Surprise History
Diversified Healthcare reported revenues of $356.52 million in the last reported quarter, representing a year-over-year change of +10.4%. EPS of -$0.28 for the same period compares with -$0.06 a year ago.
Compared to the Zacks Consensus Estimate of $359.63 million, the reported revenues represent a surprise of -0.86%. The EPS surprise was -57.14%.
Over the last four quarters, the company surpassed EPS estimates just once. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Diversified Healthcare is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Diversified Healthcare. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217774/here-is-what-to-know-beyond-why-diversified-healthcare-trust-dhc-is-a-trending-stock
| 2024-01-30T23:40:59Z
|
blocked_url
|
Paypal (PYPL - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this technology platform and digital payments company have returned +3.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Internet - Software industry, to which Paypal belongs, has gained 8.2% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Paypal is expected to post earnings of $1.36 per share for the current quarter, representing a year-over-year change of +9.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.4%.
The consensus earnings estimate of $4.98 for the current fiscal year indicates a year-over-year change of +20.6%. This estimate has changed -1.1% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $5.50 indicates a change of +10.6% from what Paypal is expected to report a year ago. Over the past month, the estimate has changed -0.8%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Paypal.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Paypal, the consensus sales estimate for the current quarter of $7.88 billion indicates a year-over-year change of +6.8%. For the current and next fiscal years, $29.63 billion and $31.92 billion estimates indicate +7.7% and +7.7% changes, respectively.
Last Reported Results and Surprise History
Paypal reported revenues of $7.42 billion in the last reported quarter, representing a year-over-year change of +8.4%. EPS of $1.30 for the same period compares with $1.08 a year ago.
Compared to the Zacks Consensus Estimate of $7.39 billion, the reported revenues represent a surprise of +0.37%. The EPS surprise was +6.56%.
Over the last four quarters, Paypal surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Paypal is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Paypal. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217775/investors-heavily-search-paypal-holdings-inc-pypl-here-is-what-you-need-to-know
| 2024-01-30T23:41:01Z
|
blocked_url
|
Bank of America (BAC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this nation's second-largest bank have returned -0.2%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Banks - Major Regional industry, which Bank of America falls in, has gained 1.7%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Bank of America is expected to post earnings of $0.79 per share, indicating a change of -16% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.2% over the last 30 days.
The consensus earnings estimate of $3.20 for the current fiscal year indicates a year-over-year change of -6.4%. This estimate has changed -1.1% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $3.39 indicates a change of +5.9% from what Bank of America is expected to report a year ago. Over the past month, the estimate has changed -0.1%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Bank of America is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Bank of America, the consensus sales estimate for the current quarter of $25.57 billion indicates a year-over-year change of -2.6%. For the current and next fiscal years, $100.84 billion and $102.4 billion estimates indicate +2.3% and +1.6% changes, respectively.
Last Reported Results and Surprise History
Bank of America reported revenues of $21.96 billion in the last reported quarter, representing a year-over-year change of -10.5%. EPS of $0.70 for the same period compares with $0.85 a year ago.
Compared to the Zacks Consensus Estimate of $24.07 billion, the reported revenues represent a surprise of -8.79%. The EPS surprise was +1.45%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Bank of America is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Bank of America. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217776/investors-heavily-search-bank-of-america-corporation-bac-here-is-what-you-need-to-know
| 2024-01-30T23:41:07Z
|
blocked_url
|
IBM (IBM - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this technology and consulting company have returned +14.4%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Computer - Integrated Systems industry, which IBM falls in, has gained 10.2%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, IBM is expected to post earnings of $1.59 per share, indicating a change of +16.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +5.2% over the last 30 days.
The consensus earnings estimate of $10.04 for the current fiscal year indicates a year-over-year change of +4.4%. This estimate has changed +2.7% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $10.57 indicates a change of +5.3% from what IBM is expected to report a year ago. Over the past month, the estimate has changed +1.3%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, IBM is rated Zacks Rank #2 (Buy).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For IBM, the consensus sales estimate for the current quarter of $14.54 billion indicates a year-over-year change of +2%. For the current and next fiscal years, $63.63 billion and $66.53 billion estimates indicate +2.9% and +4.6% changes, respectively.
Last Reported Results and Surprise History
IBM reported revenues of $17.38 billion in the last reported quarter, representing a year-over-year change of +4.1%. EPS of $3.87 for the same period compares with $3.60 a year ago.
Compared to the Zacks Consensus Estimate of $17.28 billion, the reported revenues represent a surprise of +0.59%. The EPS surprise was +2.38%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates just once over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
IBM is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about IBM. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
International Business Machines Corporation (IBM) - free report >>
|
https://www.zacks.com/stock/news/2217777/international-business-machines-corporation-ibm-is-attracting-investor-attention-here-is-what-you-should-know
| 2024-01-30T23:41:13Z
|
blocked_url
|
JPMorgan Chase & Co. (JPM - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this company have returned +1.6%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Banks - Major Regional industry, which JPMorgan Chase & Co. falls in, has gained 1.7%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
JPMorgan Chase & Co. is expected to post earnings of $4.20 per share for the current quarter, representing a year-over-year change of +2.4%. Over the last 30 days, the Zacks Consensus Estimate has changed +2.1%.
The consensus earnings estimate of $15.74 for the current fiscal year indicates a year-over-year change of -3%. This estimate has changed +1.5% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $15.56 indicates a change of -1.1% from what JPMorgan Chase & Co. is expected to report a year ago. Over the past month, the estimate has changed +1%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for JPMorgan Chase & Co.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For JPMorgan Chase & Co. the consensus sales estimate for the current quarter of $40.87 billion indicates a year-over-year change of +6.6%. For the current and next fiscal years, $159.46 billion and $160.12 billion estimates indicate +0.9% and +0.4% changes, respectively.
Last Reported Results and Surprise History
JPMorgan Chase & Co. reported revenues of $38.57 billion in the last reported quarter, representing a year-over-year change of +11.7%. EPS of $3.97 for the same period compares with $3.57 a year ago.
Compared to the Zacks Consensus Estimate of $39.16 billion, the reported revenues represent a surprise of -1.5%. The EPS surprise was +6.43%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
JPMorgan Chase & Co. is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about JPMorgan Chase & Co. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217778/jpmorgan-chase-co-jpm-is-attracting-investor-attention-here-is-what-you-should-know?-co.-(jpm)-is-attracting-investor-attention:-here-is-what-you-should-know--
| 2024-01-30T23:41:19Z
|
blocked_url
|
Intel (INTC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this world's largest chipmaker have returned -12.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Semiconductor - General industry, to which Intel belongs, has gained 17.4% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Intel is expected to post earnings of $0.34 per share for the current quarter, representing a year-over-year change of +950%. Over the last 30 days, the Zacks Consensus Estimate has changed -156.5%.
The consensus earnings estimate of $1.85 for the current fiscal year indicates a year-over-year change of +76.2%. This estimate has changed -0.5% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $2.31 indicates a change of +25.2% from what Intel is expected to report a year ago. Over the past month, the estimate has changed -3.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intel.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Intel, the consensus sales estimate for the current quarter of $12.81 billion indicates a year-over-year change of +9.3%. For the current and next fiscal years, $59.39 billion and $64.21 billion estimates indicate +9.5% and +8.1% changes, respectively.
Last Reported Results and Surprise History
Intel reported revenues of $15.41 billion in the last reported quarter, representing a year-over-year change of +9.7%. EPS of $0.54 for the same period compares with $0.10 a year ago.
Compared to the Zacks Consensus Estimate of $15.14 billion, the reported revenues represent a surprise of +1.75%. The EPS surprise was +22.73%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Intel is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intel. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217779/is-trending-stock-intel-corporation-intc-a-buy-now?
| 2024-01-30T23:41:21Z
|
blocked_url
|
Intuitive Surgical, Inc. (ISRG - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this company have returned +12.4% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Medical - Instruments industry, to which Intuitive Surgical, Inc. belongs, has gained 2.3% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Intuitive Surgical, Inc. is expected to post earnings of $1.39 per share for the current quarter, representing a year-over-year change of +13%. Over the last 30 days, the Zacks Consensus Estimate has changed -4.4%.
The consensus earnings estimate of $6.18 for the current fiscal year indicates a year-over-year change of +8.2%. This estimate has changed -2.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $7.27 indicates a change of +17.7% from what Intuitive Surgical, Inc. is expected to report a year ago. Over the past month, the estimate has changed -2.4%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Intuitive Surgical, Inc.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Intuitive Surgical, Inc. the consensus sales estimate for the current quarter of $1.87 billion indicates a year-over-year change of +10.1%. For the current and next fiscal years, $7.98 billion and $9.2 billion estimates indicate +12% and +15.3% changes, respectively.
Last Reported Results and Surprise History
Intuitive Surgical, Inc. reported revenues of $1.93 billion in the last reported quarter, representing a year-over-year change of +16.5%. EPS of $1.60 for the same period compares with $1.23 a year ago.
Compared to the Zacks Consensus Estimate of $1.93 billion, the reported revenues represent a surprise of +0.02%. The EPS surprise was +8.84%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Intuitive Surgical, Inc. is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical, Inc. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217781/intuitive-surgical-inc-isrg-is-attracting-investor-attention-here-is-what-you-should-know
| 2024-01-30T23:41:27Z
|
blocked_url
|
Pioneer Natural Resources (PXD - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this independent oil and gas company have returned +2.5% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Oil and Gas - Exploration and Production - United States industry, to which Pioneer Natural Resources belongs, has lost 5.1% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Pioneer Natural Resources is expected to post earnings of $5.79 per share for the current quarter, representing a year-over-year change of -2%. Over the last 30 days, the Zacks Consensus Estimate has changed -10.2%.
The consensus earnings estimate of $21.04 for the current fiscal year indicates a year-over-year change of -31.2%. This estimate has changed -9.9% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $21.52 indicates a change of +2.2% from what Pioneer Natural Resources is expected to report a year ago. Over the past month, the estimate has changed -9.9%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Pioneer Natural Resources.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Pioneer Natural Resources, the consensus sales estimate for the current quarter of $5.21 billion indicates a year-over-year change of +2.1%. For the current and next fiscal years, $19.44 billion and $21.44 billion estimates indicate -20% and +10.3% changes, respectively.
Last Reported Results and Surprise History
Pioneer Natural Resources reported revenues of $5 billion in the last reported quarter, representing a year-over-year change of -17.9%. EPS of $5.83 for the same period compares with $7.48 a year ago.
Compared to the Zacks Consensus Estimate of $5.23 billion, the reported revenues represent a surprise of -4.3%. The EPS surprise was +5.42%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Pioneer Natural Resources is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Pioneer Natural Resources. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217782/investors-heavily-search-pioneer-natural-resources-company-pxd-here-is-what-you-need-to-know
| 2024-01-30T23:41:33Z
|
blocked_url
|
Levi Strauss (LEVI - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this jeans maker have returned +0.2%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Retail - Apparel and Shoes industry, which Levi Strauss falls in, has gained 2.4%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Levi Strauss is expected to post earnings of $0.23 per share, indicating a change of -32.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -44.9% over the last 30 days.
The consensus earnings estimate of $1.26 for the current fiscal year indicates a year-over-year change of +14.6%. This estimate has changed -6.5% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $1.44 indicates a change of +14.6% from what Levi Strauss is expected to report a year ago. Over the past month, the estimate has changed -4.6%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Levi Strauss is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Levi Strauss, the consensus sales estimate for the current quarter of $1.56 billion indicates a year-over-year change of -7.5%. For the current and next fiscal years, $6.33 billion and $6.69 billion estimates indicate +2.5% and +5.7% changes, respectively.
Last Reported Results and Surprise History
Levi Strauss reported revenues of $1.64 billion in the last reported quarter, representing a year-over-year change of +3.4%. EPS of $0.44 for the same period compares with $0.34 a year ago.
Compared to the Zacks Consensus Estimate of $1.66 billion, the reported revenues represent a surprise of -1.18%. The EPS surprise was +4.76%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates two times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Levi Strauss is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Levi Strauss. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217783/investors-heavily-search-levi-strauss-co-levi-here-is-what-you-need-to-know?-co.-(levi):-here-is-what-you-need-to-know
| 2024-01-30T23:41:39Z
|
blocked_url
|
Ardmore Shipping (ASC - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this shipping company have returned +16.5% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Transportation - Shipping industry, to which Ardmore Shipping belongs, has gained 10.5% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Ardmore Shipping is expected to post earnings of $0.59 per share, indicating a change of -54.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days.
The consensus earnings estimate of $2.68 for the current fiscal year indicates a year-over-year change of -28.3%. This estimate has changed +0.7% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $2.13 indicates a change of -20.5% from what Ardmore Shipping is expected to report a year ago. Over the past month, the estimate has changed +1%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Ardmore Shipping is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Ardmore Shipping, the consensus sales estimate of $60.6 million for the current quarter points to a year-over-year change of -35.1%. The $258.96 million and $222.02 million estimates for the current and next fiscal years indicate changes of -11.3% and -14.3%, respectively.
Last Reported Results and Surprise History
Ardmore Shipping reported revenues of $56.3 million in the last reported quarter, representing a year-over-year change of -41.6%. EPS of $0.49 for the same period compares with $1.54 a year ago.
Compared to the Zacks Consensus Estimate of $53.94 million, the reported revenues represent a surprise of +4.38%. The EPS surprise was +13.95%.
Over the last four quarters, Ardmore Shipping surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Ardmore Shipping is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Ardmore Shipping. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217788/here-is-what-to-know-beyond-why-ardmore-shipping-corporation-asc-is-a-trending-stock
| 2024-01-30T23:41:41Z
|
blocked_url
|
Annaly Capital Management (NLY - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this real estate investment trust have returned +2.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks REIT and Equity Trust industry, to which Annaly belongs, has gained 0.2% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Annaly is expected to post earnings of $0.64 per share for the current quarter, representing a year-over-year change of -28.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -3.8%.
The consensus earnings estimate of $2.82 for the current fiscal year indicates a year-over-year change of -33.2%. This estimate has changed -2.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $2.64 indicates a change of -6.4% from what Annaly is expected to report a year ago. Over the past month, the estimate has changed -2.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Annaly.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Annaly, the consensus sales estimate for the current quarter of $296 million indicates a year-over-year change of +119.1%. For the current and next fiscal years, $239 million and $1.23 billion estimates indicate -83.7% and +413.4% changes, respectively.
Last Reported Results and Surprise History
Annaly reported revenues of $-45.33 million in the last reported quarter, representing a year-over-year change of -116.3%. EPS of $0.66 for the same period compares with $1.06 a year ago.
Compared to the Zacks Consensus Estimate of $330 million, the reported revenues represent a surprise of -113.74%. The EPS surprise was +1.54%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Annaly is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Annaly. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217789/investors-heavily-search-annaly-capital-management-inc-nly-here-is-what-you-need-to-know
| 2024-01-30T23:41:47Z
|
blocked_url
|
Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor.
But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns.
Enter the Zacks Rank.
What is the Zacks Rank?
The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, that makes building a winning portfolio easier.
There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise.
Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform.
Magnitude is the size of the recent change in the consensus estimate for the current and next fiscal years.
Upside is the difference between the most accurate estimate, which is calculated by Zacks, and the consensus estimate.
Surprise is made up of a company's last few quarters' earnings per share surprises; companies with a positive earnings surprise are more likely to beat expectations in the future.
Each factor is given a raw score, which is recalculated every night and compiled into the Zacks Rank. Utilizing this data, stocks are put into five different groups: Strong Buy, Buy, Hold, Sell, and Strong Sell.
The Power of Institutional Investors
The Zacks Rank also allows individual investors, or retail investors, to benefit from the power of institutional investors.
These professionals manage the trillions of dollars invested in hedge funds, mutual funds, and investment banks, and studies have shown that they can and do move the market because of the large amounts of money they invest with. Thus, the market tends to move in the same direction as institutional investors.
In order to determine the fair value of a company and its shares, institutional investors design valuation models that focus on earnings and earnings estimates. Because if you raise earnings estimates, it then creates a higher fair value for a company and its stock price.
With these changes, institutional investors will act, usually buying stocks with rising estimates and selling those with falling estimates. An increase in earnings expectations can potentially lead to higher stock prices and bigger gains for the investor.
Since it can often take weeks, if not months, for an institutional investor to build a position (given their size), retail investors who get in at the first sign of upward earnings estimate revisions have a distinct advantage over these larger investors, and can benefit from the expected institutional buying that will follow.
Not only can the Zacks Rank help you take advantage of trends in earnings estimate revisions, but it can also provide a way to get into stocks that are highly sought after by professionals.
How to Invest with the Zacks Rank
The Zacks Rank is known for transforming investment portfolios. In fact, a portfolio of Zacks Rank #1 (Strong Buy) stocks has beaten the market in 26 of the last 32 years, with an average annual return of +25.41%.
Moreover, stocks with a new #1 (Strong Buy) ranking have some of the biggest profit potential, while those that fell to a #4 (Sell) or #5 (Strong Sell) have some of the worst.
Let's take a look at Textron (TXT - Free Report) , which was added to the Zacks Rank #1 list on January 30, 2024.
Textron Inc., incorporated in 1923, is a global multi-industry company that manufactures aircraft, automotive engine components and industrial tools. It also offers solutions and services for aircraft, fastening systems, and industrial products and components. Its products include commercial and military helicopters, light- and mid-size business jets, plastic fuel tanks, automotive trim products, golf carts and utility vehicles, turf-car equipment, industrial pumps and gears. It is a commercial finance company in select markets. Textron is known globally for its most recognizable and valuable brand names, such as Bell Helicopter, Cessna Aircraft Company, Jacobsen, Kautex, E-Z-GO and Greenlee.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.18 to $5.95 per share. TXT boasts an average earnings surprise of 13.5%.
Earnings are forecasted to see growth of 6.4% for the current fiscal year, and sales are expected to increase 6.8%.
TXT has been moving higher over the past four weeks as well, up 6.7% compared to the S&P 500's gain of 3.4%.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Textron should be on investors' shortlist.
If you want even more information on the Zacks Ranks, or one of our many other investing strategies, check out the Zacks Education home page.
Discover Today's Top Stocks
Our private Zacks #1 Rank List, based on our quantitative Zacks Rank stock-rating system, has more than doubled the S&P 500 since 1988. Applying the Zacks Rank in your own trading can boost your investing returns on your very next trade. See Today's Zacks #1 Rank List >>
|
https://www.zacks.com/stock/news/2217790/this-top-aerospace-stock-is-a-strong-buy-why-it-should-be-on-your-radar
| 2024-01-30T23:41:54Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and Roper Technologies, Inc. (ROP - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Roper is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ROP in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $4.40 per share for ROP, compared to a broader Zacks Consensus Estimate of $4.33 per share. This suggests that analysts have very recently bumped up their estimates for ROP, giving the stock a Zacks Earnings ESP of +1.69% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that ROP has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Roper, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2217793/is-a-surprise-coming-for-roper-rop-this-earnings-season?
| 2024-01-30T23:42:00Z
|
blocked_url
|
The fourth-quarter 2023 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies.
The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson (JNJ - Free Report) reported better-than-expected fourth-quarter results. It beat estimates for earnings as well as sales, primarily due to the strong performance of its Innovative Medicines segment.
Per the Earnings Trends report, as of Jan 24, 8.3% of the companies in the Medical sector — representing 25.9% of the sector’s market capitalization — reported quarterly earnings. Of these, 60% outperformed on earnings while 100% beat revenue estimates. Earnings increased 3.3% year over year, while revenues increased 7.9%. Overall, fourth-quarter earnings of the Medical sector are expected to decline 22.2%, while sales are expected to rise 4.2% from the year-ago quarter.
Novo Nordisk (NVO - Free Report) , Novartis (NVS - Free Report) and GSK plc (GSK - Free Report) are scheduled to release their respective fourth-quarter earnings reports before the opening bell on Jan 31.
Let’s see how these biotech/pharma companies might have performed in the soon-to-be-reported quarter.
Novo Nordisk
Novo Nordisk has a mixed earnings surprise history. NVO’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, matched once and missed on another occasion, delivering an average earnings surprise of 0.58%. In the last reported quarter, NVO beat earnings estimates by 5.8%.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
For the quarter to be reported, Novo Nordisk has an Earnings ESP of +0.89% and a Zacks Rank #1, indicating a likely positive surprise. The Zacks Consensus Estimate for the company’s current quarter adjusted EPS is pegged at 66 cents. You can see the complete list of today’s Zacks #1 Rank stocks here.
Novo Nordisk’s fourth-quarter revenues are likely to have been boosted by the higher sales of Diabetes and Obesity Care products. Diabetes medicines like Ozempic and Rybelsus are expected to have put up a strong performance in the to-be-reported quarter. Sales of Obesity Care drugs, Saxenda and Wegovy, are likely to have been encouraging.
Novartis
Novartis has an impressive track record, beating earnings expectations in each of the trailing four quarters and delivering a four-quarter average earnings surprise of 6.99%. In the last reported quarter, NVS beat earnings estimates by 2.35%.
For the quarter to be reported, Novartis has an Earnings ESP of +3.39% and a Zacks Rank #3, suggesting a likely earnings beat this time around. The Zacks Consensus Estimate for Novartis’ earnings is pegged at $1.67 per share.
Novartis’ revenues in the fourth quarter of 2023 are likely to have been driven by key drugs like Kesimpta, Entresto, Kisqali and Pluvicto. With the successful spin-off of the Sandoz business in October 2023, Novartis operates as a single global operating segment, focused on innovative medicines. It now concentrates on four core therapeutic areas (cardiovascular, renal and metabolic, immunology, neuroscience and oncology).
GSK
GSK has an impeccable earnings track record, having surpassed estimates in each of the trailing four quarters and delivering a beat of 11.02% on average. In the last reported quarter, GSK beat earnings estimates by 15.6%.
For the quarter to be reported, GSK has an Earnings ESP of +0.63% and a Zacks Rank #3, suggesting a likely earnings beat this time around. The Zacks Consensus Estimate for GSK’s earnings is pegged at 80 cents per share.
In the fourth quarter of 2023, higher revenues from the sales of GSK’s newer products like Arexvy, Cabenuva, Dovato, Trelegy Ellipta and Shingrix are likely to have offset the decline in sales of older HIV drugs and respiratory medicines due to generic erosion and competitive pressure.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
GSK PLC Sponsored ADR (GSK) - free report >>
Novartis AG (NVS) - free report >>
|
https://www.zacks.com/stock/news/2217797/drug-biotech-stocks-q4-earnings-due-on-jan-31-nvo-nvs-gsk?-gsk
| 2024-01-30T23:42:01Z
|
blocked_url
|
Sysco (SYY - Free Report) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.14%. A quarter ago, it was expected that this food distributor would post earnings of $1.02 per share when it actually produced earnings of $1.07, delivering a surprise of 4.90%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Sysco
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Sysco shares have added about 2.8% since the beginning of the year versus the S&P 500's gain of 3.3%.
What's Next for Sysco?
While Sysco has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Sysco: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.98 on $19.83 billion in revenues for the coming quarter and $4.33 on $79.5 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Food - Miscellaneous is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Smucker (SJM - Free Report) , has yet to report results for the quarter ended January 2024.
This food maker is expected to post quarterly earnings of $2.26 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level.
Smucker's revenues are expected to be $2.21 billion, down 0.1% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2217800/sysco-syy-surpasses-q2-earnings-estimates
| 2024-01-30T23:42:08Z
|
blocked_url
|
Vista Outdoor Inc. (VSTO - Free Report) is scheduled to report third-quarter fiscal 2024 results on Jan 31. In the last reported quarter, the company delivered a negative earnings surprise of 3%.
How are Estimates Placed?
The Zacks Consensus Estimate for fiscal third-quarter earnings per share is pegged at 84 cents, suggesting a decline of 35.4% from $1.30 reported in the year-ago quarter.
For revenues, the consensus mark is pegged at $687.9 million, indicating a decline of 8.8% from the prior-year quarter’s reported figure.
Factors to Note
The quarterly performance of Vista Outdoor is anticipated to have been negatively impacted by reduced shipments in various categories within the Sporting Products segment. Lower volume can be attributed to cautious approach of channel partners in purchasing, caused by concerns about inventory levels and short-term consumer pressures in the Outdoor Products businesses. Higher costs are likely to have hurt the company’s bottom line.
The Zacks Consensus Estimate for total Outdoor Products and Sporting Products revenues is pegged at $325 million and $369 million, indicating a decline of 7.9% and 8.2%, respectively, from the year-ago quarter’s levels.
What the Zacks Model Unveils
Our proven model doesn’t conclusively predict an earnings beat for Vista Outdoor this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Vista Outdoor has an Earnings ESP 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Vista Outdoor has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Poised to Beat Earnings Estimates
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat.
MGM Resorts International (MGM - Free Report) has an Earnings ESP of +14.99% and a Zacks Rank #3.
Shares of MGM Resorts have increased 9.5% in the past year. MGM’s earnings beat estimates in each of the trailing four quarters, the average surprise being 292.7%.
Boyd Gaming Corporation (BYD - Free Report) has an Earnings ESP of +1.10% and a Zacks Rank #3.
Shares of Boyd Gaming have gained 6.8% in the past year. BYD’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 6.9%.
Hasbro, Inc. (HAS - Free Report) has an Earnings ESP of +5.05% and a Zacks Rank #3.
Shares of Hasbro have declined 13.5% in the past three months. HAS’ earnings beat estimates in two of the trailing four quarters and missed twice, the negative surprise being 22.4%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Hasbro, Inc. (HAS) - free report >>
MGM Resorts International (MGM) - free report >>
|
https://www.zacks.com/stock/news/2217804/factors-setting-the-tone-for-vista-outdoor-vsto-q3-earnings
| 2024-01-30T23:42:14Z
|
blocked_url
|
Wall Street analysts expect CBOE Global (CBOE - Free Report) to post quarterly earnings of $2.02 per share in its upcoming report, which indicates a year-over-year increase of 12.2%. Revenues are expected to be $505.08 million, up 10.5% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 1.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific CBOE metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Market data fees' of $77.24 million. The estimate indicates a change of +7.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Access and capacity fees' should come in at $89.72 million. The estimate indicates a year-over-year change of +8.5%.
Analysts predict that the 'Revenues- Other revenue' will reach $16.89 million. The estimate suggests a change of +46.8% year over year.
It is projected by analysts that the 'Revenues- Regulatory fees' will reach $51.03 million. The estimate indicates a change of -57.6% from the prior-year quarter.
The consensus estimate for 'Revenues- Transaction and clearing fees' stands at $567.03 million. The estimate suggests a change of -21.1% year over year.
Analysts forecast 'Revenues less cost of revenues- Net transaction and clearing fees' to reach $368.77 million. The estimate points to a change of +16.3% from the year-ago quarter.
Analysts expect 'Average Daily Volume by Product - Options - Index options' to come in at 3,980.00 thousand. The estimate compares to the year-ago value of 3,359 thousand.
Analysts' assessment points toward 'Average Daily Volume by Product - Futures' reaching 232.66 thousand. The estimate is in contrast to the year-ago figure of 193 thousand.
Based on the collective assessment of analysts, 'Average Daily Notional Volume by Product - Global FX' should arrive at 46.99 billion. The estimate compares to the year-ago value of 40.8 billion.
View all Key Company Metrics for CBOE here>>>
Shares of CBOE have demonstrated returns of +2.8% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #2 (Buy), CBOE is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217805/gear-up-for-cboe-cboe-q4-earnings-wall-street-estimates-for-key-metrics
| 2024-01-30T23:42:20Z
|
blocked_url
|
The upcoming report from OneWater Marine (ONEW - Free Report) is expected to reveal quarterly loss of $0.30 per share, indicating a decline of 149.2% compared to the year-ago period. Analysts forecast revenues of $370.33 million, representing an increase of 1% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 7.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific OneWater Marine metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- New boat' will reach $232.30 million. The estimate indicates a year-over-year change of -0.1%.
Analysts expect 'Revenues- Service, parts & other' to come in at $69.30 million. The estimate indicates a year-over-year change of -0.4%.
The average prediction of analysts places 'Revenues- Finance & insurance income' at $10.20 million. The estimate indicates a change of +14.2% from the prior-year quarter.
The consensus estimate for 'Revenues- Pre-owned boat' stands at $63.97 million. The estimate indicates a year-over-year change of +14.7%.
Analysts' assessment points toward 'Gross Profit- New boat' reaching $44.93 million. The estimate compares to the year-ago value of $57.15 million.
The collective assessment of analysts points to an estimated 'Gross Profit- Service, parts & other' of $28.37 million. The estimate compares to the year-ago value of $28.43 million.
According to the collective judgment of analysts, 'Gross Profit- Pre-owned boat' should come in at $13.00 million. Compared to the current estimate, the company reported $15.47 million in the same quarter of the previous year.
View all Key Company Metrics for OneWater Marine here>>>
Over the past month, OneWater Marine shares have recorded returns of -22.1% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #2 (Buy), ONEW will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217806/exploring-analyst-estimates-for-onewater-marine-onew-q1-earnings-beyond-revenue-and-eps
| 2024-01-30T23:42:22Z
|
blocked_url
|
Analysts on Wall Street project that Aon (AON - Free Report) will announce quarterly earnings of $4.07 per share in its forthcoming report, representing an increase of 4.6% year over year. Revenues are projected to reach $3.35 billion, increasing 7.1% from the same quarter last year.
The current level reflects an upward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Aon metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenue- Reinsurance Solutions' of $312.14 million. The estimate indicates a year-over-year change of +11.1%.
The average prediction of analysts places 'Revenue- Health Solutions' at $734.43 million. The estimate indicates a change of +8.3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Wealth Solutions' should arrive at $369.16 million. The estimate points to a change of +4.6% from the year-ago quarter.
Analysts forecast 'Revenue- Commercial Risk Solutions' to reach $1.94 billion. The estimate indicates a change of +6.3% from the prior-year quarter.
Analysts' assessment points toward 'Consolidated - Organic Revenue Growth' reaching 5.9%. Compared to the current estimate, the company reported 5% in the same quarter of the previous year.
The consensus among analysts is that 'Reinsurance Solutions - Organic Revenue Growth' will reach 8.3%. Compared to the present estimate, the company reported 9% in the same quarter last year.
Analysts expect 'Wealth Solutions - Organic Revenue Growth' to come in at 3.7%. Compared to the present estimate, the company reported 6% in the same quarter last year.
It is projected by analysts that the 'Commercial Risk Solutions - Organic Revenue Growth' will reach 4.8%. Compared to the present estimate, the company reported 4% in the same quarter last year.
The combined assessment of analysts suggests that 'Health Solutions - Organic Revenue Growth' will likely reach 7.8%. The estimate is in contrast to the year-ago figure of 7%.
View all Key Company Metrics for Aon here>>>
Shares of Aon have demonstrated returns of +2.5% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #3 (Hold), AON is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217807/seeking-clues-to-aon-aon-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?-a-peek-into-wall-street-projections-for-key-metrics
| 2024-01-30T23:42:28Z
|
blocked_url
|
Wall Street analysts expect Century Communities (CCS - Free Report) to post quarterly earnings of $2.27 per share in its upcoming report, which indicates a year-over-year decline of 16.2%. Revenues are expected to be $915.91 million, down 22.3% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Century Communities metrics that Wall Street analysts commonly model and monitor.
Analysts forecast 'Revenues- Financial services revenues' to reach $21.01 million. The estimate points to a change of -8.9% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Total homebuilding revenues' should come in at $894.93 million. The estimate points to a change of -22.6% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Home sales revenues' reaching $892.93 million. The estimate indicates a change of -22.5% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Land sales and other revenues' at $3.00 million. The estimate suggests a change of -21.6% year over year.
Analysts predict that the 'Home Deliveries - Homes' will reach 2,361. Compared to the present estimate, the company reported 2,903 in the same quarter last year.
The consensus estimate for 'Home Deliveries - Average Sales Price' stands at $378.21. Compared to the current estimate, the company reported $396.90 in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Backlog - Homes' should arrive at 1,553. The estimate is in contrast to the year-ago figure of 1,810.
The collective assessment of analysts points to an estimated 'Net New Home Contracts' of 2,022. The estimate compares to the year-ago value of 1,258.
The consensus among analysts is that 'Selling Communities at period end' will reach 255. Compared to the current estimate, the company reported 208 in the same quarter of the previous year.
View all Key Company Metrics for Century Communities here>>>
Century Communities shares have witnessed a change of -3% in the past month, in contrast to the Zacks S&P 500 composite's +3.4% move. With a Zacks Rank #3 (Hold), CCS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217808/ahead-of-century-communities-ccs-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T23:42:34Z
|
blocked_url
|
Wall Street analysts expect W.W. Grainger (GWW - Free Report) to post quarterly earnings of $8.03 per share in its upcoming report, which indicates a year-over-year increase of 12.5%. Revenues are expected to be $4.05 billion, up 6.4% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some W.W. Grainger metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- High-Touch Solutions N.A.' will likely reach $3.27 billion. The estimate indicates a year-over-year change of +6.4%.
Analysts' assessment points toward 'Net Sales- Other' reaching $67.99 million. The estimate suggests a change of +11.5% year over year.
The consensus estimate for 'Net Sales- Endless Assortment' stands at $701.86 million. The estimate indicates a change of +4.8% from the prior-year quarter.
Analysts expect 'Total Reported Growth' to come in at 6.3%. Compared to the present estimate, the company reported 13.2% in the same quarter last year.
View all Key Company Metrics for W.W. Grainger here>>>
Shares of W.W. Grainger have demonstrated returns of +8.1% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #3 (Hold), GWW is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217809/seeking-clues-to-ww-grainger-gww-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?-a-peek-into-wall-street-projections-for-key-metrics
| 2024-01-30T23:42:41Z
|
blocked_url
|
The upcoming report from Regeneron (REGN - Free Report) is expected to reveal quarterly earnings of $10.48 per share, indicating a decline of 16.6% compared to the year-ago period. Analysts forecast revenues of $3.26 billion, representing a decrease of 4.7% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Regeneron metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Net product sales' will reach $1.82 billion. The estimate indicates a year-over-year change of +7%.
Based on the collective assessment of analysts, 'Revenues- Collaboration' should arrive at $1.35 billion. The estimate indicates a year-over-year change of -15%.
The collective assessment of analysts points to an estimated 'Revenues- Other Revenue' of $122.32 million. The estimate indicates a change of -4.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Dupixent (dupilumab)- Total' should come in at $3.13 billion. The estimate indicates a year-over-year change of +27.8%.
The average prediction of analysts places 'Revenues- Eylea (Aflibercept)- US' at $1.45 billion. The estimate indicates a change of -3.1% from the prior-year quarter.
The consensus estimate for 'Revenues- Praluent (alirocumab)- US' stands at $41.83 million. The estimate suggests a change of +17.8% year over year.
Analysts expect 'Revenues- Kevzara (sarilumab)- ROW' to come in at $40.80 million. The estimate points to a change of +17.9% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Dupixent (dupilumab)- US' will reach $2.43 billion. The estimate indicates a year-over-year change of +25.5%.
Analysts' assessment points toward 'Revenues- Eylea (Aflibercept)- ROW' reaching $871.52 million. The estimate indicates a year-over-year change of +3.9%.
The combined assessment of analysts suggests that 'Revenues- Libtayo- US' will likely reach $163.07 million. The estimate indicates a year-over-year change of +48.2%.
Analysts forecast 'Revenues- Libtayo- ROW' to reach $88.94 million. The estimate indicates a change of +51.3% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Evkeeza- US' will reach $18.90 million. The estimate indicates a change of +26% from the prior-year quarter.
View all Key Company Metrics for Regeneron here>>>
Over the past month, Regeneron shares have recorded returns of +8.8% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #1 (Strong Buy), REGN will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217810/gear-up-for-regeneron-regn-q4-earnings-wall-street-estimates-for-key-metrics
| 2024-01-30T23:42:42Z
|
blocked_url
|
The upcoming report from Boot Barn (BOOT - Free Report) is expected to reveal quarterly earnings of $1.80 per share, indicating an increase of 3.5% compared to the year-ago period. Analysts forecast revenues of $520.43 million, representing an increase of 1.1% year over year.
Over the last 30 days, there has been a downward revision of 1.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Boot Barn metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Stores operating at end of period' of 382. Compared to the current estimate, the company reported 333 in the same quarter of the previous year.
Analysts expect 'Average store square footage, end of period' to come in at 10,855. The estimate compares to the year-ago value of 10,806.
The consensus estimate for 'Stores Opened/Acquired' stands at 11. Compared to the present estimate, the company reported 12 in the same quarter last year.
View all Key Company Metrics for Boot Barn here>>>
Over the past month, Boot Barn shares have recorded returns of -1.7% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #3 (Hold), BOOT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217811/stay-ahead-of-the-game-with-boot-barn-boot-q3-earnings-wall-streets-insights-on-key-metrics
| 2024-01-30T23:42:48Z
|
blocked_url
|
Wall Street analysts forecast that Bristol Myers Squibb (BMY - Free Report) will report quarterly earnings of $1.56 per share in its upcoming release, pointing to a year-over-year decline of 14.3%. It is anticipated that revenues will amount to $11.11 billion, exhibiting a decline of 2.6% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 11.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Bristol Myers metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Net Sales- Recent LOE Products- Revlimid' at $1.35 billion. The estimate suggests a change of -40.1% year over year.
Analysts' assessment points toward 'Net Sales- In-Line Products- Orencia' reaching $963.62 million. The estimate suggests a change of +5.5% year over year.
The consensus estimate for 'Net Sales- Recent LOE Products- Abraxane' stands at $223.71 million. The estimate suggests a change of +25% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- New Product Portfolio- Inrebic' of $29.79 million. The estimate points to a change of +29.5% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- New Product Portfolio- Inrebic- U.S.' will reach $20.21 million. The estimate indicates a change of +18.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Net Sales- In-Line Products- Opdivo- U.S.' should come in at $1.35 billion. The estimate points to a change of +7% from the year-ago quarter.
Analysts expect 'Net Sales- Recent LOE Products- Abraxane- U.S.' to come in at $158.73 million. The estimate suggests a change of +36.8% year over year.
Based on the collective assessment of analysts, 'Net Sales- Recent LOE Products- Abraxane- International' should arrive at $62.42 million. The estimate suggests a change of -0.9% year over year.
Analysts forecast 'Net Sales- In-Line Products- Pomalyst/Imnovid- U.S.' to reach $590.90 million. The estimate suggests a change of -5.5% year over year.
The combined assessment of analysts suggests that 'Net Sales- In-Line Products- Pomalyst/Imnovid- International' will likely reach $263.88 million. The estimate indicates a year-over-year change of +4.7%.
It is projected by analysts that the 'Net Sales- Recent LOE Products- Revlimid- U.S.' will reach $1.20 billion. The estimate suggests a change of -40.8% year over year.
Analysts predict that the 'Net Sales- Recent LOE Products- Revlimid- International' will reach $170.23 million. The estimate points to a change of -27.9% from the year-ago quarter.
View all Key Company Metrics for Bristol Myers here>>>
Shares of Bristol Myers have demonstrated returns of -2.8% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #3 (Hold), BMY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217812/wall-streets-insights-into-key-metrics-ahead-of-bristol-myers-bmy-q4-earnings
| 2024-01-30T23:42:54Z
|
blocked_url
|
Wall Street analysts expect Church & Dwight (CHD - Free Report) to post quarterly earnings of $0.64 per share in its upcoming report, which indicates a year-over-year increase of 3.2%. Revenues are expected to be $1.51 billion, up 5.3% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Church & Dwight metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Net sales- Total Consumer Net Sales' at $1.43 billion. The estimate indicates a change of +6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net sales- Consumer- Consumer Domestic' of $1.18 billion. The estimate indicates a year-over-year change of +5.6%.
Analysts' assessment points toward 'Net sales- Consumer- Consumer International' reaching $250.73 million. The estimate suggests a change of +8.4% year over year.
The consensus among analysts is that 'Net sales- Specialty Products Division' will reach $79.01 million. The estimate indicates a change of -5.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net sales- Consumer- Consumer Domestic - Household Products' will likely reach $615.73 million. The estimate suggests a change of +5% year over year.
Analysts forecast 'Net sales- Consumer- Consumer Domestic - Personal Care Products' to reach $569.77 million. The estimate points to a change of +6.6% from the year-ago quarter.
View all Key Company Metrics for Church & Dwight here>>>
Shares of Church & Dwight have demonstrated returns of +5.3% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #2 (Buy), CHD is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217813/seeking-clues-to-church-dwight-chd-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?-a-peek-into-wall-street-projections-for-key-metrics
| 2024-01-30T23:43:00Z
|
blocked_url
|
Wall Street analysts expect Navient (NAVI - Free Report) to post quarterly earnings of $0.77 per share in its upcoming report, which indicates a year-over-year increase of 1.3%. Revenues are expected to be $210.76 million, down 9.2% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 6.6% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Navient metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Asset recovery and business processing revenue' should come in at $86.81 million. The estimate compares to the year-ago value of $72 million.
Based on the collective assessment of analysts, 'Servicing revenue' should arrive at $15.59 million. Compared to the current estimate, the company reported $17 million in the same quarter of the previous year.
Analysts predict that the 'Other income' will reach $5.09 million. Compared to the current estimate, the company reported $10 million in the same quarter of the previous year.
Analysts forecast 'Net interest income (loss)- Federal Education Loans' to reach $110.33 million. Compared to the current estimate, the company reported $115 million in the same quarter of the previous year.
It is projected by analysts that the 'Non-interest income (loss) / Total other income- Other' will reach $1.04 million. Compared to the present estimate, the company reported $3 million in the same quarter last year.
The collective assessment of analysts points to an estimated 'Non-interest income (loss) / Total other income- Consumer Lending' of $3.60 million. The estimate is in contrast to the year-ago figure of $3 million.
The average prediction of analysts places 'Non-interest income (loss) / Total other income- Business Processing' at $83.13 million. Compared to the current estimate, the company reported $70 million in the same quarter of the previous year.
Analysts' assessment points toward 'Non-interest income (loss) / Total other income- Federal Education Loans' reaching $18.23 million. Compared to the present estimate, the company reported $23 million in the same quarter last year.
The combined assessment of analysts suggests that 'Total Non Interest Income / Total other income' will likely reach $113.23 million. Compared to the current estimate, the company reported $109 million in the same quarter of the previous year.
The consensus estimate for 'Net Interest Income' stands at $209.98 million. Compared to the present estimate, the company reported $223 million in the same quarter last year.
The consensus among analysts is that 'Net interest income (loss)- Consumer Lending' will reach $128.41 million. The estimate is in contrast to the year-ago figure of $147 million.
View all Key Company Metrics for Navient here>>>
Shares of Navient have demonstrated returns of -2.4% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #1 (Strong Buy), NAVI is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217815/what-analyst-projections-for-key-metrics-reveal-about-navient-navi-q4-earnings
| 2024-01-30T23:43:02Z
|
blocked_url
|
Wall Street analysts expect Sally Beauty (SBH - Free Report) to post quarterly earnings of $0.36 per share in its upcoming report, which indicates a year-over-year decline of 30.8%. Revenues are expected to be $927.18 million, down 3.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Sally Beauty metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- Sally Beauty Supply' will likely reach $527.94 million. The estimate indicates a year-over-year change of -3.9%.
Analysts expect 'Net Sales- Beauty Systems Group' to come in at $397.88 million. The estimate suggests a change of -2.4% year over year.
The collective assessment of analysts points to an estimated 'Comparable sales growth - Sally Beauty Supply' of -1.9%. Compared to the current estimate, the company reported 3% in the same quarter of the previous year.
The consensus among analysts is that 'Number of stores at end-of-period - Beauty Systems Group' will reach 1,340. Compared to the current estimate, the company reported 1,352 in the same quarter of the previous year.
Analysts forecast 'Number of stores at end-of-period - Total' to reach 4,485. Compared to the present estimate, the company reported 4,498 in the same quarter last year.
Analysts' assessment points toward 'Number of stores at end-of-period - Sally Beauty Supply' reaching 3,145. The estimate is in contrast to the year-ago figure of 3,146.
View all Key Company Metrics for Sally Beauty here>>>
Over the past month, Sally Beauty shares have recorded returns of -5.4% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #2 (Buy), SBH will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217816/ahead-of-sally-beauty-sbh-q1-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T23:43:08Z
|
blocked_url
|
The upcoming report from Central Pacific Financial (CPF - Free Report) is expected to reveal quarterly earnings of $0.48 per share, indicating a decline of 35.1% compared to the year-ago period. Analysts forecast revenues of $61.18 million, representing a decrease of 9.9% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Central Pacific Financial metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Total nonperforming assets' should come in at $9.71 million. The estimate is in contrast to the year-ago figure of $5.25 million.
Analysts forecast 'Efficiency Ratio' to reach 64.8%. The estimate compares to the year-ago value of 59.6%.
Based on the collective assessment of analysts, 'Net Interest Margin' should arrive at 2.8%. Compared to the present estimate, the company reported 3.2% in the same quarter last year.
The consensus among analysts is that 'Total nonaccrual loans' will reach $9.71 million. Compared to the current estimate, the company reported $5.25 million in the same quarter of the previous year.
Analysts expect 'Average Balance - Total interest earning assets' to come in at $7.15 billion. Compared to the current estimate, the company reported $7.10 billion in the same quarter of the previous year.
Analysts' assessment points toward 'Net Interest Income (FTE)' reaching $50.88 million. Compared to the current estimate, the company reported $56.49 million in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Total noninterest Income/ Total other operating income' will likely reach $10.50 million. Compared to the current estimate, the company reported $11.60 million in the same quarter of the previous year.
Analysts predict that the 'Net Interest Income' will reach $50.69 million. The estimate compares to the year-ago value of $56.29 million.
View all Key Company Metrics for Central Pacific Financial here>>>
Over the past month, Central Pacific Financial shares have recorded returns of +0.7% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #3 (Hold), CPF will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217817/central-pacific-financial-cpf-q4-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-30T23:43:15Z
|
blocked_url
|
Wall Street analysts expect Coursera (COUR - Free Report) to post break-even quarterly earnings per share in its upcoming report, which indicates a year-over-year increase of 100%. Revenues are expected to be $163.64 million, up 15.1% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Coursera metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Consumer' of $95.36 million. The estimate indicates a change of +19.5% from the prior-year quarter.
Analysts expect 'Revenues- Degrees' to come in at $12.50 million. The estimate points to a change of +5.1% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Enterprise' will reach $55.76 million. The estimate indicates a change of +10.4% from the prior-year quarter.
The average prediction of analysts places 'Total registered learners' at 141.69 million. The estimate is in contrast to the year-ago figure of 118 million.
Analysts predict that the 'Number of Degrees Students' will reach 21,138. The estimate is in contrast to the year-ago figure of 18,103.
The combined assessment of analysts suggests that 'Paid Enterprise Customers' will likely reach 1,339. Compared to the present estimate, the company reported 1,149 in the same quarter last year.
View all Key Company Metrics for Coursera here>>>
Over the past month, Coursera shares have recorded returns of +6.7% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #3 (Hold), COUR will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217818/ahead-of-coursera-cour-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T23:43:21Z
|
blocked_url
|
In its upcoming report, Brookfield Renewable Energy Partners (BEP - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.02 per share, reflecting an increase of 87.5% compared to the same period last year. Revenues are forecasted to be $743.15 million, representing a year-over-year increase of 15.2%.
The consensus EPS estimate for the quarter has been revised 15.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Brookfield Renewable metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Operating Revenue- Wind- North America' reaching $105.42 million. The estimate indicates a change of +15.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Operating Revenue- Wind- Asia' should come in at $16.56 million. The estimate suggests a change of +38% year over year.
Based on the collective assessment of analysts, 'Operating Revenue- Wind- Brazil' should arrive at $10.76 million. The estimate indicates a change of +34.6% from the prior-year quarter.
Analysts expect 'Operating Revenue- Wind- Europe' to come in at $33.46 million. The estimate points to a change of +4.6% from the year-ago quarter.
The consensus among analysts is that 'Actual Generation - Wind - Total' will reach 1,957.48 GWh. The estimate is in contrast to the year-ago figure of 1,539 GWh.
Analysts predict that the 'Actual Generation - Hydroelectric - Total' will reach 4,882.06 GWh. The estimate is in contrast to the year-ago figure of 4,609 GWh.
The consensus estimate for 'Actual Generation - Hydroelectric - North America' stands at 2,875.52 GWh. The estimate is in contrast to the year-ago figure of 2,427 GWh.
It is projected by analysts that the 'Actual Generation - Wind - Brazil' will reach 192.61 GWh. The estimate compares to the year-ago value of 141 GWh.
The collective assessment of analysts points to an estimated 'Actual Generation - Wind - Asia' of 248.02 GWh. Compared to the present estimate, the company reported 159 GWh in the same quarter last year.
Analysts forecast 'Actual Generation - Wind - Europe' to reach 254.87 GWh. Compared to the current estimate, the company reported 234 GWh in the same quarter of the previous year.
The average prediction of analysts places 'Actual Generation - Wind - North America' at 1,240.26 GWh. The estimate compares to the year-ago value of 1,005 GWh.
The combined assessment of analysts suggests that 'Actual Generation - Hydroelectric - Colombia' will likely reach 1,032.21 GWh. Compared to the current estimate, the company reported 1,222 GWh in the same quarter of the previous year.
View all Key Company Metrics for Brookfield Renewable here>>>
Over the past month, Brookfield Renewable shares have recorded returns of +1.4% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #5 (Strong Sell), BEP will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217819/brookfield-renewable-bep-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures
| 2024-01-30T23:43:22Z
|
blocked_url
|
Wall Street analysts expect Brinker International (EAT - Free Report) to post quarterly earnings of $0.94 per share in its upcoming report, which indicates a year-over-year increase of 23.7%. Revenues are expected to be $1.08 billion, up 5.8% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 3.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Brinker International metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Franchise and other revenues' reaching $10.37 million. The estimate indicates a year-over-year change of +8%.
Based on the collective assessment of analysts, 'Total Revenue- Company Restaurant Sales' should arrive at $1.07 billion. The estimate suggests a change of +5.6% year over year.
The collective assessment of analysts points to an estimated 'Revenue- Company sales- Maggiano's' of $142.72 million. The estimate indicates a change of +1.9% from the prior-year quarter.
Analysts expect 'Revenue- Company sales- Chili's' to come in at $918.34 million. The estimate indicates a change of +5.6% from the prior-year quarter.
The consensus among analysts is that 'Comparable store sales - Chili's - YoY change' will reach 6.7%. Compared to the current estimate, the company reported 8% in the same quarter of the previous year.
Analysts forecast 'Franchise restaurants - Total' to reach 472. Compared to the current estimate, the company reported 466 in the same quarter of the previous year.
Analysts predict that the 'Comparable store sales - Maggiano's - YoY change' will reach 3.6%. Compared to the present estimate, the company reported 21.2% in the same quarter last year.
According to the collective judgment of analysts, 'Company owned restaurants - Maggiano's - Domestic locations' should come in at 50. Compared to the current estimate, the company reported 51 in the same quarter of the previous year.
The average prediction of analysts places 'Company owned restaurants - Chili's' at 1,132. The estimate compares to the year-ago value of 1,131.
It is projected by analysts that the 'Company owned restaurants - Total' will reach 1,181. The estimate compares to the year-ago value of 1,182.
The consensus estimate for 'Total restaurants - Brinker International' stands at 1,639. The estimate compares to the year-ago value of 1,648.
The combined assessment of analysts suggests that 'Franchise restaurants - Chili's - International' will likely reach 370. Compared to the current estimate, the company reported 363 in the same quarter of the previous year.
View all Key Company Metrics for Brinker International here>>>
Shares of Brinker International have experienced a change of -5.8% in the past month compared to the +3.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), EAT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217820/what-analyst-projections-for-key-metrics-reveal-about-brinker-international-eat-q2-earnings
| 2024-01-30T23:43:29Z
|
blocked_url
|
Wall Street analysts expect Conmed (CNMD - Free Report) to post quarterly earnings of $1.11 per share in its upcoming report, which indicates a year-over-year increase of 164.3%. Revenues are expected to be $332.94 million, up 32.7% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Conmed metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net Sales- Orthopedic Surgery' stands at $137.97 million. The estimate indicates a change of +19.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- General Surgery' should arrive at $189.99 million. The estimate indicates a year-over-year change of +40%.
Analysts predict that the 'Net Sales- Single-use Products' will reach $270.50 million. The estimate points to a change of +27.7% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Capital Products' reaching $58.69 million. The estimate points to a change of +50.5% from the year-ago quarter.
View all Key Company Metrics for Conmed here>>>
Conmed shares have witnessed a change of -13.3% in the past month, in contrast to the Zacks S&P 500 composite's +3.4% move. With a Zacks Rank #3 (Hold), CNMD is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217821/ahead-of-conmed-cnmd-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T23:43:35Z
|
blocked_url
|
In its upcoming report, BrightView Holdings (BV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.05 per share, reflecting an increase of 600% compared to the same period last year. Revenues are forecasted to be $651.07 million, representing a year-over-year decrease of 0.7%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific BrightView metrics that are commonly monitored and projected by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenue- Maintenance Services' will likely reach $469.78 million. The estimate indicates a change of -2.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Development Services' should arrive at $183.01 million. The estimate points to a change of +4.9% from the year-ago quarter.
Analysts forecast 'Revenue- Maintenance Services - Snow Removal Services' to reach $54.91 million. The estimate suggests a change of -11.1% year over year.
According to the collective judgment of analysts, 'Revenue- Maintenance Services - Landscape Maintenance Services' should come in at $414.86 million. The estimate points to a change of -1.6% from the year-ago quarter.
The consensus among analysts is that 'Adjusted EBITDA- Development Services' will reach $18.02 million. The estimate compares to the year-ago value of $16.50 million.
The consensus estimate for 'Adjusted EBITDA- Maintenance Services' stands at $50.68 million. Compared to the present estimate, the company reported $50.50 million in the same quarter last year.
View all Key Company Metrics for BrightView here>>>
Over the past month, shares of BrightView have returned +6.5% versus the Zacks S&P 500 composite's +3.4% change. Currently, BV carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217822/countdown-to-brightview-bv-q1-earnings-a-look-at-estimates-beyond-revenue-and-eps
| 2024-01-30T23:43:41Z
|
blocked_url
|
In its upcoming report, AbbVie (ABBV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.79 per share, reflecting a decline of 22.5% compared to the same period last year. Revenues are forecasted to be $14.06 billion, representing a year-over-year decrease of 7%.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific AbbVie metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Net Revenue- Eye Care- Total' should arrive at $567.50 million. The estimate indicates a change of -3.8% from the prior-year quarter.
It is projected by analysts that the 'Net Revenue- Aesthetics- Total' will reach $1.35 billion. The estimate points to a change of +4.7% from the year-ago quarter.
Analysts predict that the 'Net Revenue- Immunology- Total' will reach $6.79 billion. The estimate suggests a change of -14.3% year over year.
Analysts' assessment points toward 'Net Revenue- Hematologic Oncology- Total' reaching $1.44 billion. The estimate points to a change of -11.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Revenue- Humira- US' should come in at $2.70 billion. The estimate indicates a year-over-year change of -46%.
The collective assessment of analysts points to an estimated 'Net Revenue- Immunology- Skyrizi- International' of $282.32 million. The estimate indicates a change of +63.2% from the prior-year quarter.
The average prediction of analysts places 'Net Revenue- Immunology- Skyrizi- US' at $2.13 billion. The estimate indicates a change of +51.5% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Revenue- Humira- International' will likely reach $482.89 million. The estimate indicates a year-over-year change of -15.7%.
Analysts expect 'Net Revenue- Rinvoq- International' to come in at $316.55 million. The estimate suggests a change of +55.2% year over year.
The consensus among analysts is that 'Net Revenue- Rinvoq- US' will reach $877.55 million. The estimate points to a change of +55% from the year-ago quarter.
The consensus estimate for 'Net Revenue- Immunology- Total International' stands at $1.08 billion. The estimate indicates a change of +13.9% from the prior-year quarter.
Analysts forecast 'Net Revenue- Immunology- Total US' to reach $5.70 billion. The estimate indicates a year-over-year change of -18.2%.
View all Key Company Metrics for AbbVie here>>>
Over the past month, shares of AbbVie have returned +5.8% versus the Zacks S&P 500 composite's +3.4% change. Currently, ABBV carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217823/unveiling-abbvie-abbv-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T23:43:43Z
|
blocked_url
|
Wall Street analysts expect Methanex (MEOH - Free Report) to post quarterly earnings of $0.28 per share in its upcoming report, which indicates a year-over-year decline of 61.6%. Revenues are expected to be $901.21 million, down 8.6% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific Methanex metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Sales volume in tonnes - Methanex-produced methanol' should come in at 1,627.62 KTon. Compared to the present estimate, the company reported 1,360 KTon in the same quarter last year.
Analysts expect 'Sales volume in tonnes - Purchased methanol' to come in at 849.02 KTon. The estimate compares to the year-ago value of 1,095 KTon.
The consensus among analysts is that 'Average realized methanol price ($/tonne)' will reach 330.70 $/Ton. The estimate compares to the year-ago value of 373 $/Ton.
Analysts forecast 'Sales volume in tonnes - Total' to reach 2,740.73 KTon. The estimate compares to the year-ago value of 2,647 KTon.
Analysts predict that the 'Sales volume in tonnes - Commission sales' will reach 264.08 KTon. The estimate compares to the year-ago value of 192 KTon.
View all Key Company Metrics for Methanex here>>>
Over the past month, shares of Methanex have returned -4% versus the Zacks S&P 500 composite's +3.4% change. Currently, MEOH carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217824/countdown-to-methanex-meoh-q4-earnings-wall-street-forecasts-for-key-metrics
| 2024-01-30T23:43:49Z
|
blocked_url
|
The upcoming report from Cimpress (CMPR - Free Report) is expected to reveal quarterly earnings of $1.24 per share, indicating an increase of 369.6% compared to the year-ago period. Analysts forecast revenues of $901.13 million, representing an increase of 6.6% year over year.
The current level reflects an upward revision of 0.9% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Cimpress metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Revenue- Vista' should arrive at $471.79 million. The estimate points to a change of +7.8% from the year-ago quarter.
Analysts predict that the 'Revenue- All Other Businesses' will reach $62.77 million. The estimate indicates a change of +4.6% from the prior-year quarter.
The consensus estimate for 'Revenue- National Pen' stands at $118.29 million. The estimate indicates a year-over-year change of -1.9%.
View all Key Company Metrics for Cimpress here>>>
Over the past month, Cimpress shares have recorded returns of -1.1% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #1 (Strong Buy), CMPR will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217825/what-analyst-projections-for-key-metrics-reveal-about-cimpress-cmpr-q2-earnings
| 2024-01-30T23:43:55Z
|
blocked_url
|
The upcoming report from Cigna (CI - Free Report) is expected to reveal quarterly earnings of $6.52 per share, indicating an increase of 31.5% compared to the year-ago period. Analysts forecast revenues of $48.82 billion, representing an increase of 6.7% year over year.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Cigna metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenues- Evernorth Health Services' stands at $38.44 billion. The estimate indicates a year-over-year change of +6.2%.
According to the collective judgment of analysts, 'Revenues- Cigna Healthcare' should come in at $12.60 billion. The estimate indicates a change of +13.1% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Cigna Healthcare- Premiums' will reach $10.67 billion. The estimate suggests a change of +13% year over year.
Analysts predict that the 'Revenues- Cigna Healthcare- Premiums- U.S. Commercial - Other' will reach $357.48 million. The estimate indicates a change of +1.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Medical Care Ratio - Cigna Healthcare' will likely reach 83.7%. The estimate compares to the year-ago value of 84%.
Based on the collective assessment of analysts, 'Covered Lives By Funding Type - Medical Customers - Total U.S. Commercial insured' should arrive at 2,227.27 thousand. Compared to the current estimate, the company reported 2,238 thousand in the same quarter of the previous year.
It is projected by analysts that the 'Medical Customers - Total' will reach 19,626.26 thousand. The estimate compares to the year-ago value of 18,004 thousand.
The collective assessment of analysts points to an estimated 'Covered Lives By Funding Type - Medical Customers - U.S. Government - Medicare Advantage' of 603.50 thousand. The estimate is in contrast to the year-ago figure of 529 thousand.
Analysts' assessment points toward 'Total Medical Customers - Medicare Part D' reaching 2,534.75 thousand. The estimate compares to the year-ago value of 2,874 thousand.
The average prediction of analysts places 'Covered Lives By Market Segment - Medical Customers - International Health' at 1,530.91 thousand. Compared to the present estimate, the company reported 1,798 thousand in the same quarter last year.
Analysts forecast 'Covered Lives By Market Segment - Medical Customers - U.S. Commercial - Total' to reach 16,046.38 thousand. The estimate is in contrast to the year-ago figure of 14,852 thousand.
Analysts expect 'Covered Lives By Market Segment - Medical Customers - U.S. Government' to come in at 1,966.00 thousand. The estimate compares to the year-ago value of 1,354 thousand.
View all Key Company Metrics for Cigna here>>>
Over the past month, Cigna shares have recorded returns of -0.2% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #3 (Hold), CI will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217826/curious-about-cigna-ci-q4-performance-explore-wall-street-estimates-for-key-metrics?-explore-wall-street-estimates-for-key-metrics
| 2024-01-30T23:44:01Z
|
blocked_url
|
The upcoming report from Accuray (ARAY - Free Report) is expected to reveal quarterly loss of $0.07 per share, indicating a decline of 250% compared to the year-ago period. Analysts forecast revenues of $107.11 million, representing a decrease of 6.7% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Accuray metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Net revenue- Services' to come in at $50.70 million. The estimate indicates a year-over-year change of -1.6%.
Analysts predict that the 'Net revenue- Products' will reach $56.41 million. The estimate points to a change of -10.8% from the year-ago quarter.
The average prediction of analysts places 'Order Backlog' at $462.45 million. The estimate compares to the year-ago value of $515.24 million.
The combined assessment of analysts suggests that 'Net Orders' will likely reach $61.16 million. The estimate compares to the year-ago value of $40.87 million.
According to the collective judgment of analysts, 'Gross Orders' should come in at $81.74 million. Compared to the present estimate, the company reported $79.04 million in the same quarter last year.
View all Key Company Metrics for Accuray here>>>
Shares of Accuray have demonstrated returns of +1.1% over the past month compared to the Zacks S&P 500 composite's +3.4% change. With a Zacks Rank #3 (Hold), ARAY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217827/unveiling-accuray-aray-q2-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T23:44:03Z
|
blocked_url
|
Wall Street analysts expect LyondellBasell (LYB - Free Report) to post quarterly earnings of $1.29 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $10.38 billion, up 1.8% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some LyondellBasell metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Revenues- Advanced Polymer Solutions' reaching $966.84 million. The estimate suggests a change of -12.4% year over year.
It is projected by analysts that the 'Revenues- Olefins and Polyolefins- Americas' will reach $3.08 billion. The estimate points to a change of +13.7% from the year-ago quarter.
Analysts expect 'Revenues- Olefins and Polyolefins- Europe, Asia, International' to come in at $2.66 billion. The estimate suggests a change of +11% year over year.
The average prediction of analysts places 'Revenues- Refining and Oxyfuels' at $1.98 billion. The estimate indicates a year-over-year change of -24.7%.
Analysts forecast 'Revenues- Technology' to reach $155.93 million. The estimate indicates a change of +7.5% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Intermediates & Derivatives' of $2.91 billion. The estimate indicates a year-over-year change of +13.7%.
According to the collective judgment of analysts, 'EBITDA- Olefins & Polyolefins- Americas' should come in at $601.94 million. Compared to the present estimate, the company reported $359 million in the same quarter last year.
Analysts predict that the 'EBITDA- Intermediates & Derivatives' will reach $364.43 million. The estimate compares to the year-ago value of $291 million.
The combined assessment of analysts suggests that 'EBITDA- Advanced Polymer Solutions' will likely reach $16.02 million. Compared to the current estimate, the company reported $3 million in the same quarter of the previous year.
The consensus estimate for 'EBITDA- Technology' stands at $47.69 million. Compared to the present estimate, the company reported $59 million in the same quarter last year.
Based on the collective assessment of analysts, 'EBITDA- Refining' should arrive at $41.48 million. Compared to the present estimate, the company reported $249 million in the same quarter last year.
View all Key Company Metrics for LyondellBasell here>>>
Over the past month, LyondellBasell shares have recorded returns of +0.2% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #3 (Hold), LYB will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217828/unveiling-lyondellbasell-lyb-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T23:44:09Z
|
blocked_url
|
The upcoming report from Charter Communications (CHTR - Free Report) is expected to reveal quarterly earnings of $8.90 per share, indicating an increase of 15.7% compared to the year-ago period. Analysts forecast revenues of $13.72 billion, representing an increase of 0.3% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Charter metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenues- Residential- Video' at $3.96 billion. The estimate indicates a year-over-year change of -6.8%.
Analysts expect 'Revenues- Advertising sales' to come in at $427.14 million. The estimate indicates a year-over-year change of -23.5%.
Analysts' assessment points toward 'Revenues- Commercial- Total' reaching $1.79 billion. The estimate suggests a change of +2.2% year over year.
The consensus estimate for 'Revenues- Residential- Mobile service' stands at $615.23 million. The estimate indicates a change of -29.8% from the prior-year quarter.
Analysts predict that the 'Residential - Total Video Customers' will reach 13,527.25 thousand. Compared to the present estimate, the company reported 14,497 thousand in the same quarter last year.
The combined assessment of analysts suggests that 'Total Mobile Lines' will likely reach 7,743.81 thousand. The estimate compares to the year-ago value of 5,292 thousand.
Based on the collective assessment of analysts, 'Small and Medium Business - Customer Relationships' should arrive at 2,230.34 thousand. The estimate compares to the year-ago value of 2,207 thousand.
The consensus among analysts is that 'Residential - Customer Relationships' will reach 30,015.48 thousand. The estimate compares to the year-ago value of 29,988 thousand.
It is projected by analysts that the 'Total Mobile Lines - Net Additions' will reach 570.41 thousand. The estimate compares to the year-ago value of 615 thousand.
The collective assessment of analysts points to an estimated 'Residential - Total Voice Customers' of 6,721.15 thousand. The estimate compares to the year-ago value of 7,697 thousand.
According to the collective judgment of analysts, 'Customer Relationships - SMB - Net Additions' should come in at 6.34 thousand. The estimate compares to the year-ago value of 12 thousand.
Analysts forecast 'Residential - Total Internet Customers' to reach 28,615.03 thousand. Compared to the current estimate, the company reported 28,412 thousand in the same quarter of the previous year.
View all Key Company Metrics for Charter here>>>
Over the past month, Charter shares have recorded returns of -2% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #4 (Sell), CHTR will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217829/charter-chtr-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures
| 2024-01-30T23:44:16Z
|
blocked_url
|
Have you been paying attention to shares of First Bancorp (FBP - Free Report) ? Shares have been on the move with the stock up 5.7% over the past month. The stock hit a new 52-week high of $17.45 in the previous session. First Bancorp has gained 5.7% since the start of the year compared to the 19.8% move for the Zacks Finance sector and the 10.6% return for the Zacks Banks - Southeast industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on January 24, 2024, First Bancorp reported EPS of $0.49 versus consensus estimate of $0.39 while it beat the consensus revenue estimate by 1.12%.
For the current fiscal year, First Bancorp is expected to post earnings of $1.62 per share on $931.52 million in revenues. This represents a -5.26% change in EPS on a 0.18% change in revenues. For the next fiscal year, the company is expected to earn $1.84 per share on $959.6 million in revenues. This represents a year-over-year change of 13.58% and 3.01%, respectively.
Valuation Metrics
First Bancorp may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
First Bancorp has a Value Score of B. The stock's Growth and Momentum Scores are D and A, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 10.7X current fiscal year EPS estimates, which is not in-line with the peer industry average of 12X. On a trailing cash flow basis, the stock currently trades at 9.5X versus its peer group's average of 8.6X. Additionally, the stock has a PEG ratio of 1.53. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, First Bancorp currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if First Bancorp fits the bill. Thus, it seems as though First Bancorp shares could have a bit more room to run in the near term.
|
https://www.zacks.com/stock/news/2217830/first-bancorp-fbp-hit-a-52-week-high-can-the-run-continue?
| 2024-01-30T23:44:22Z
|
blocked_url
|
Dolby Laboratories Inc (DLB - Free Report) is slated to report first-quarter fiscal 2024 results on Feb 1.
The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $310.9 million, indicating a decrease of 7.2% from the year-ago quarter’s reported figure. The consensus mark for earnings per share (EPS) is pegged at 89 cents, indicating a year-over-year decrease of 19.8%.
The company expects GAAP EPS of 44-59 cents and non-GAAP EPS of 80-95 cents on revenues of $300-$330 million for the fiscal first quarter.
Factors to Note
The company’s quarterly performance is likely to have been affected by lower shipments in broadcast and consumer electronics due to macroeconomic weakness. Rising research and development costs to fend off stiff competition continue to strain DLB’s margins.
Our estimate for broadcast and consumer electronics sales is pegged at $108.1 million and $41 million, indicating a decline of 7.9% and 25.6%, respectively, from the year-ago reported figure.
However, the company’s performance is likely to have benefited from the increasing adoption of Dolby Atmos, Dolby Vision, and new imaging patents. The company expects revenues from these businesses to grow by a high single digit in fiscal 2024.
Also, the company’s initiatives to boost growth in newer areas like music, automotive and user-generated content with the help of Dolby Vision Capture bodes well. In the last quarter, the company signed an agreement with a Chinese car manufacturer — BYD — to launch a car with Dolby Atmos.
Apart from this, the increasing adoption of Dolby Atmos Music to broadcast high-quality content to Dolby-enabled devices is a major tailwind. The company is likely to have benefited from the adoption of Dolby.io, which is a platform that enables developers to build immersive online experiences. The growing demand for high-quality with ultra-low latency applications is further tailwinds.
What Our Model Says
Our proven model does not predict an earnings beat for Dolby this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
DLB has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With a Favorable Combination
Here are some stocks you may consider, as our proven model shows that these have the right mix of elements to beat on earnings this time around
Apple (AAPL - Free Report) has an Earnings ESP of +1.96% and carries a Zacks Rank #3 at present. Apple is scheduled to release first-quarter fiscal 2024 results on Feb 1. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Apple’s to-be-reported quarter’s earnings and revenues is pegged at $2.09 per share and $117.6 billion, respectively. Shares of AAPL have gained 32.9% in the past year.
Alphabet (GOOGL - Free Report) has an Earnings ESP of +2.26% and a Zacks Rank #3 at present. Alphabet is scheduled to release fourth-quarter 2023 results on Jan 30.
The Zacks Consensus Estimate for Apple’s to-be-reported quarter’s earnings and revenues is pegged at $1.60 per share and $70.7 billion, respectively. Shares of GOOGL have gained 55.3% in the past year.
Expedia Group (EXPE - Free Report) has an Earnings ESP of +4.79% and a Zacks Rank #3 at present. Expedia is scheduled to release its fourth-quarter 2023 results on Feb 8.
The Zacks Consensus Estimate for EXPE’s to-be-reported quarter’s earnings and revenues is pegged at $1.67 per share and $2.88 billion, respectively. Shares of EXPE have gained 34.7% in the past year.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Dolby Laboratories (DLB) - free report >>
Apple Inc. (AAPL) - free report >>
|
https://www.zacks.com/stock/news/2217831/factors-to-note-ahead-of-dolbys-dlb-q1-earnings-release
| 2024-01-30T23:44:23Z
|
blocked_url
|
Ball Corporation (BALL - Free Report) is scheduled to report fourth-quarter 2023 results on Feb 1, before the opening bell.
Q3 Performance
In the last reported quarter, Ball Corp’s earnings increased year over year and beat the Zacks Consensus Estimate. However, the top line fell year over year and missed the estimate. BALL surpassed the consensus estimate in three of the four trailing quarters and missed in one, the average surprise being 6.7%.
Q4 Estimates
The Zacks Consensus Estimate for BALL’s fourth-quarter earnings per share is pegged at 77 cents, suggesting an improvement of 75% from the prior-year quarter’s reported levels. The consensus estimate for total sales is pegged at $3.52 billion, indicating a year-over-year decline of 0.7%.
Factors to Note
Ball Corp has lately been witnessing weaker-than-expected demand, as customer spending has been muted amid higher retail prices, particularly in the United States. This is likely to be reflected in the company’s fourth-quarter results. High input and labor costs due to supply constraints are anticipated to have impacted the company’s performance in the quarter.
However, BALL has been focused on improving its efficiency and reducing costs, which is likely to have negated these impacts and aided margins in the to-be-reported quarter.
Our estimate for the Beverage packaging, North and Central America segment’s net sales is pegged at $1,532 million for the December-end quarter, indicating 1.3% year-over-year growth. The segment’s operating income is estimated at $167 million, suggesting growth of 37% from the year-ago quarter’s actual.
We expect the segment’s volume to have improved 5.4% in the quarter, backed by the execution of strategic initiatives.
Our model predicts the Beverage Packaging, Europe segment’s sales to be $634 million for the to-be-reported quarter, indicating a 15% drop from the year-ago quarter’s reported figure. We expect a volume decline of 6.2% for this segment.
However, the focus on reducing costs is likely to have partially negated these headwinds. The segment’s operating income is projected at $104 million, suggesting 121% year-over-year growth.
We expect the Beverage Packaging, South America segment’s net sales to be $681 million, suggesting 10.9% growth from the year-ago period’s reported level. The consensus estimate for the segment’s operating income is pegged at $74.8 million, suggesting a 4.1% decline from the year-ago quarter’s reported level. Our model predicts a volume increase of 15.2% for the segment.
Our estimate for the Aerospace segment's revenues is pegged at $496 million for the period under discussion, indicating a year-over-year decline of 1.9%. The segment is expected to have witnessed the impacts of supply-chain inefficiencies. However, the segment has been winning defense, climate change and Earth-monitoring contracts to provide mission-critical programs and technologies to the U.S. government, defense, intelligence, reconnaissance and surveillance customers.
The segment’s operating income is projected at $106 million, suggesting 141% growth from the prior-year quarter’s reported figure.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Ball Corp this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Earnings ESP: BALL has an Earnings ESP of +2.33%.
Zacks Rank: Currently, the company carries a Zacks Rank #4 (Sell).
Price Performance
Shares of Ball Corp have lost 0.7% in the past year compared with the industry's 1.8% decline.
Image Source: Zacks Investment Research
Stocks to Consider
Here are some Industrial Products stocks, which according to our model, have the right combination of elements to beat on earnings in their upcoming releases.
Kubota Corporation (KUBTY - Free Report) , which is expected to release fourth-quarter 2023 earnings soon, has an Earnings ESP of +6.94%.
The Zacks Consensus Estimate for KUBTY’s earnings for the fourth quarter is pegged at 72 cents per share. It currently sports a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
The consensus estimate for the quarterly earnings has moved 7% north in the past 60 days. It has an average trailing four-quarter earnings surprise of 31.2%.
Reliance Steel & Aluminum Co. (RS - Free Report) , set to release earnings on Feb 15, has an Earnings ESP of +3.35% and a Zacks Rank of 2, at present.
The Zacks Consensus Estimate for RS’ fourth-quarter earnings is pegged at $3.88 per share. Earnings estimates have been unchanged in the past 60 days. The company has an average trailing four-quarter earnings surprise of 10.6%.
Ingersoll Rand Inc. (IR - Free Report) , scheduled to release earnings on Feb 15, currently has an Earnings ESP of +0.98% and a Zacks Rank of 3.
The consensus estimate for Ingersoll Rand’s earnings for the fourth quarter is pegged at 76 cents per share. Earnings estimates have been unchanged in the past 60 days. It has an average trailing four-quarter earnings surprise of 16.1%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Reliance Steel & Aluminum Co. (RS) - free report >>
Ingersoll Rand Inc. (IR) - free report >>
|
https://www.zacks.com/stock/news/2217832/ball-corp-ball-to-report-q4-earnings-whats-in-store?
| 2024-01-30T23:44:30Z
|
blocked_url
|
W.W. Grainger, Inc. (GWW - Free Report) is scheduled to report fourth-quarter 2023 results on Feb 2, before the opening bell.
Q4 Estimates
The Zacks Consensus Estimate for GWW’s fourth-quarter revenues is pegged at $4.05 billion, indicating growth of 6.4% from the year-ago quarter’s reported figure. Organic growth for the quarter is expected to be 6.2%. The consensus mark for earnings per share is pegged at $8.03, implying an improvement of 12.5% from the prior-year quarter's level.
Q3 Results
In the last reported quarter, Grainger’s earnings surpassed the Zacks Consensus Estimate, while revenues missed the same. The top and bottom lines increased year over year. GWW's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.2%.
What the Zacks Model Indicates
Our proven model doesn’t conclusively predict an earnings beat for Grainger this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here.
Earnings ESP: Grainger has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Grainger currently carries a Zacks Rank #3.
Factors to Note
Grainger has been witnessing strong growth in core and non-pandemic product sales for the past few quarters. The company’s product mix has been stabilizing, as customers are returning to normal operations post-pandemic.
Also, GWW has been focusing on improving the end-to-end customer experience by making investments in its e-commerce and digital capabilities, and executing improvement initiatives within its supply chain. These factors are likely to have contributed to the company’s fourth-quarter performance. We expect organic daily sales growth to be 6.4% for the quarter.
The company’s High-Touch Solutions North America segment is expected to have benefited from strength in commercial, transportation and heavy manufacturing, strong revenue growth across its North American regions, and an expansion in large and midsize customers. Our model projects quarterly organic daily sales to grow 7.1% from the year-ago quarter's level.
Management has been witnessing market-beating growth in the High-Touch Solutions market compared with the U.S. MRO (maintenance, repair and operating) market. This outperformance can be attributed to strategic activities, such as building advantaged MRO solutions, delivering unparalleled customer services, and offering differentiated sales and services.
We expect the segment’s revenues to be $3,290 million for the fourth quarter of 2023, up 7.1% from the fourth-quarter 2022 levels.
GWW’s Endless Assortment segment is likely to have benefited from strong customer acquisition and repeat business in the quarter to be reported. Our model predicts quarterly organic daily sales to grow 3.3% from the prior-year levels.
Customer growth at MonotaRO is expected to have positively impacted the segment’s revenues. Our model predicts the Endless Assortment segment’s revenues to be $692 million, up 3.3% from the prior-year quarter’s reported figure.
However, GWW has been witnessing elevated material and freight costs for some time. This, coupled with higher operating costs and incremental SG&A expenses due to higher technology investments, is likely to have negatively impacted its margins in the quarter under review.
Price Performance
Grainger's shares have risen 53.6% in a year compared with the industry’s growth of 21.2%.
Image Source: Zacks Investment Research
Stocks to Consider
Here are some Industrial Products stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases.
Kubota Corporation (KUBTY - Free Report) , which is expected to release fourth-quarter 2023 earnings soon, has an Earnings ESP of +6.94% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for KUBTY’s earnings for the fourth quarter is pegged at 72 cents per share. The consensus estimate for quarterly earnings has moved 7% north in the past 60 days. It has a trailing four-quarter earnings surprise of 31.2%, on average.
Reliance Steel & Aluminum Co. (RS - Free Report) , which is set to release earnings on Feb 15, has an Earnings ESP of +3.35% and a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for RS’ fourth-quarter earnings is pegged at $3.88 per share, which remained unchanged in the past 60 days. RS has a trailing four-quarter earnings surprise of 10.6%, on average.
Ingersoll Rand Inc. (IR - Free Report) , which is scheduled to release earnings on Feb 15, currently has an Earnings ESP of +0.98% and a Zacks Rank of 3.
The consensus estimate for Ingersoll Rand’s fourth-quarter earnings is pegged at 76 cents per share, which remained unchanged in the past 60 days. It has a trailing four-quarter earnings surprise of 16.1%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Reliance Steel & Aluminum Co. (RS) - free report >>
W.W. Grainger, Inc. (GWW) - free report >>
|
https://www.zacks.com/stock/news/2217833/grainger-gww-set-to-report-q4-earnings-whats-in-store?
| 2024-01-30T23:44:36Z
|
blocked_url
|
RPC Inc. (RES - Free Report) reported fourth-quarter adjusted earnings of 19 cents per share, which beat the Zacks Consensus Estimate of 12 cents. However, the bottom line declined from the year-ago quarter’s level of 41 cents.
Total quarterly revenues were $395 million, down from the year-ago quarter’s level of $482 million. The top line, however, beat the Zacks Consensus Estimate of $361 million.
The better-than-expected fourth-quarter results can be attributed to the significantly higher utilization of the pressure pumping fleet. However, a drop in oil price followed by a decline in customer demands offset the positives to some extent.
Segmental Performance
Operating profit in the Technical Services segment totaled $46.4 million, lower than the year-ago quarter’s level of $110.5 million. Higher contributions from pressure pumping activities partially offset the upside.
Operating profit in the Support Services segment amounted to $5 million, lower than the year-ago quarter’s level of $6.7 million. The decline was attributed to a decrease in the activity level of rental tools and the high fixed costs involved in these service lines.
Total operating profit in the quarter was $49.2 million, down from $112.3 million reported in the year-ago quarter. The average domestic rig count was 622, marking a 19.8% decline from the year-ago quarter’s level. The average oil price in the quarter was $78.52 per barrel, down 5% year over year. The average price of natural gas was $2.74 per thousand cubic feet, down 50.6% from that recorded in the corresponding period of 2022.
Costs and Expenses
In the fourth quarter of 2023, the cost of revenues decreased to $279.4 million from $308.6 million in the prior-year period. Selling, general and administrative expenses amounted to $38.1 million, slightly lower than the year-ago quarter’s figure of $38.2 million.
Financials
RPC’s total capital expenditure for 2023 was $181 million.
As of Dec 31, RPC had cash and cash equivalents of $223.3 million. The company managed to maintain a debt-free balance sheet.
Zacks Rank & Stocks to Consider
RPC currently carries a Zack Rank #4 (Sell).
Some better-ranked players in the energy sector are Oceaneering International (OII - Free Report) , Repsol (REPYY - Free Report) and Harbour Energy (HBRIY - Free Report) . While both Oceaneering International and Repsol currently sport a Zacks Rank #1 (Strong Buy), Harbour Energy holds a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Oceaneering International is a market leading supplier of offshore equipment and technology solutions to the energy industry. The company has projected an increase in free cash flows for 2024. The bright outlook is supported by the growing market demand for its mobile robotic forklifts and underride vehicles.
Repsol is a global multi-energy company, involved in exploration and production activities as well as refining and marketing petroleum products. The company is also actively involved in transitioning toward cleaner and more sustainable energy solutions. Recently, it announced the expansion of its network of renewable fuel refilling stations in Europe, demonstrating its commitment toward a sustainable energy model.
Harbour Energy is a leading independent oil and gas company, primarily involved in upstream operations. Upon completion of the recently announced acquisition of Wintershall Dea asset portfolio, its estimated production will increase to 500,000 barrels of oil equivalent per day. The company has also done well in reducing its debt in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Oceaneering International, Inc. (OII) - free report >>
Repsol SA (REPYY) - free report >>
|
https://www.zacks.com/stock/news/2217835/rpc-res-q4-earnings-top-estimates-on-pressure-pumping
| 2024-01-30T23:44:42Z
|
blocked_url
|
Lemonade (LMND - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, LMND broke through the 20-day moving average, which suggests a short-term bullish trend.
A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.
Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend.
LMND could be on the verge of another rally after moving 8.5% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.
Once investors consider LMND's positive earnings estimate revisions, the bullish case only solidifies. No earnings estimate has been lowered in the past two months, compared to 1 raised estimates, for the current fiscal year, and the consensus estimate has increased as well.
Investors should think about putting LMND on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
|
https://www.zacks.com/stock/news/2217855/lemonade-lmnd-crossed-above-the-20-day-moving-average-what-that-means-for-investors
| 2024-01-30T23:44:48Z
|
blocked_url
|
A downtrend has been apparent in AC Immune (ACIU - Free Report) lately with too much selling pressure. The stock has declined 35.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.
Here is How to Spot Oversold Stocks
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
Why a Trend Reversal is Due for ACIU
The heavy selling of ACIU shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 29.51. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering ACIU in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 6.9% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, ACIU currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217856/down--357-in-4-weeks-heres-why-ac-immune-aciu-looks-ripe-for-a-turnaround
| 2024-01-30T23:44:55Z
|
blocked_url
|
This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.18% per year. These returns cover a period from January 1, 1988 through January 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by FIS.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
|
https://www.zacks.com/stock/news/2217857/company-news-for-jan-30-2024
| 2024-01-30T23:45:01Z
|
blocked_url
|
Offerpad Solutions Inc. (OPAD - Free Report) shares ended the last trading session 6.6% higher at $9.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.7% loss over the past four weeks.
The increased optimism in the stock can be attributed to its recent announcement of a new agent program, which marks a significant expansion of its current Agent Partnership Program.
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of +94.3%. Revenues are expected to be $256.6 million, down 62.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Offerpad Solutions Inc., the consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on OPAD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Offerpad Solutions Inc. belongs to the Zacks Real Estate - Operations industry. Another stock from the same industry, Jones Lang LaSalle (JLL - Free Report) , closed the last trading session 0.9% higher at $177.89. Over the past month, JLL has returned -6.6%.
For Jones Lang LaSalle
|
https://www.zacks.com/stock/news/2217859/offerpad-solutions-inc-opad-moves-66-higher-will-this-strength-last?
| 2024-01-30T23:45:07Z
|
blocked_url
|
The fourth-quarter earnings season for the Medical sector has begun. Per the latest Earnings Preview, quarterly results so far have improved year over year despite the ongoing macroeconomic headwinds in the form of worldwide inflationary pressure and unfavorable foreign exchange headwinds. Going by the sector’s scorecard, 8.3% of the companies in the Medical sector, constituting 25.9% of the sector’s market capitalization, reported earnings till Jan 24. Of these, 60% beat earnings estimates, while 100% beat revenue estimates. Earnings improved 3.3% year over year on 7.9% higher revenues.
However, overall fourth-quarter earnings of the Medical sector are expected to plunge 22.2% despite 4.2% revenue growth. This compares with the third-quarter earnings decline of 16.7% on revenue growth of 6.6%.
The projection reflects a declining overall operating margin scenario. Deteriorating international trade, with global inflationary pressure leading to an extremely tough situation related to raw material and labor costs, and higher medical expenses as well as freight charges have put the industry in a tight spot again. The majority of the players within this space witnessed a rise in raw material costs and other expense pressure through the fourth-quarter months. Added to this, labor-supply constraints, in the form of labordemic and global supply chain hazards, are expected to have moderated the growth process.
Medical Products Quarterly Synopsys
Replicating the market-wide trend, Medical Device stocks or the Zacks-defined Medical Products companies’ collective business growth in the fourth quarter is likely to have been significantly dampened by the ongoing macroeconomic threat in the United States and outside.
Going by the industry-wide trend, logistical challenges and increasing unit costs are likely to have weighed heavily on the corporate profitability of stocks across the board. This difficult macroenvironment continued to restrict capital investments in the fourth quarter, impacting the overall performance of the sector. At the same time, to tackle mounting expenses, companies accelerated their cost-reduction initiatives.
Added to this, through the fourth-quarter months, the companies that are into international trade faced currency headwinds.
Meanwhile, the tightened monetary policy starkly altered consumer preferences and once again put the demand for the non-essential category line of medical products businesses on the back burner. This might have, in a way, shrunk the companies’ revenues in the fourth quarter compared to the prior quarter.
Also, diagnostic testing companies might have once again witnessed a severe year-over-year decline in testing demand.
Medical products companies like Boston Scientific (BSX - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and Align Technologies (ALGN - Free Report) are likely to have been influenced by these abovementioned factors in the fourth quarter.
On a positive note, during the post-pandemic phase, the key focus of medical device R&D shifted from COVID-related PPE, testing and distant care options to point-of-care testing, heavy as well as minimally invasive implants, elective procedures and so forth. Accordingly, legacy-based business recovery and testing demand of the companies through the months of the fourth quarter are expected to have been impressive. Meanwhile, AI and robotics for the medical Internet of Things (IoT), which rose to the limelight during the pandemic phase, remained popular.
Let's take a look at three Medical Products players scheduled to announce fourth-quarter results on Jan 31.
Boston Scientific: With U.S. hospitals reporting an increase in the number of procedure volumes during the months of the fourth quarter of 2023, Boston Scientific, with its innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, is well-positioned to register decent results for this period. However, the rate of growth is expected to have remained sluggish amid a challenging supply environment in limited geographies, particularly in Europe, through the months of the fourth quarter. Further, given the ongoing inflationary situation, the business is expected to have faced the hurdle of surging labor and raw material costs, which might have weighed on BSX’s bottom line in the fourth quarter.
(Read more: What's in Store for Boston Scientific in Q4 Earnings?)
The Zacks Consensus Estimate for fourth-quarter total revenues is pegged at $3.59 billion, suggesting an improvement of 10.7% from the prior-year quarter’s reported number. The consensus mark for adjusted earnings stands at 51 cents per share, implying a 13.3% rise from the year-ago quarter’s reported figure.
Per our proven model, a stock with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates. This is not the case, as you can see below.
BSX has an Earnings ESP of 0.00% and carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Thermo Fisher: Its Analytical Instruments segment is expected to have generated strong sales in the fourth quarter, banking on chromatography, mass spectrometry and the electron microscopy businesses. Per our model, Thermo Fisher’s Analytical Instruments’ fourth-quarter revenues are estimated to be $1.95 billion, suggesting 3.7% growth year over year.
Within the Life-Science Solutions segment, the company is expected to have registered a decline due to moderation in pandemic-related revenues. Unfavorable macroeconomic conditions and foreign currency fluctuations might have impeded growth in the fourth quarter.
(Read more: What's in Store for Thermo Fisher in Q4 Earnings?)
The Zacks Consensus Estimate for Thermo Fisher’s fourth-quarter 2023 revenues is pegged at $10.74 billion, suggesting a decline of 6.2% from the year-ago reported figure. The Zacks Consensus Estimate for its fourth-quarter 2023 EPS of $5.64 indicates a year-over-year rise of 4.4%.
TMO has an Earnings ESP of 0.00% and carries a Zacks Rank #3.
Align Technologies: Despite the difficult macroeconomic challenges and soft consumer trends that Align Technologies faced throughout 2023, we expect the company’s worldwide revenues to have grown in the fourth quarter, banking on an improving volume environment. The number of Clear Aligner shipments to teenage and younger patients is likely to have been robust, driven by the continued strength of Invisalign First.
(Read more: Align Technology to Post Q4 Earnings: What's in Store?)
The Zacks Consensus Estimate for the company’s fourth-quarter 2023 revenues is pegged at $928.4 million, suggesting a rise of 2.9% from the year-ago reported figure. The Zacks Consensus Estimate for fourth-quarter 2023 earnings of $2.17 indicates a 25.4% rise from the year-ago reported figure.
ALGN has an Earnings ESP of 0.00% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Boston Scientific Corporation (BSX) - free report >>
|
https://www.zacks.com/stock/news/2217861/medical-products-q4-earnings-due-on-jan-31-bsx-tmo-algn?-algn
| 2024-01-30T23:45:13Z
|
blocked_url
|
For the quarter ended December 2023, PulteGroup (PHM - Free Report) reported revenue of $4.29 billion, down 17% over the same period last year. EPS came in at $3.28, compared to $3.63 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $4.48 billion, representing a surprise of -4.20%. The company delivered an EPS surprise of +2.50%, with the consensus EPS estimate being $3.20.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how PulteGroup performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Average Selling Price - Total: $547 compared to the $545.40 average estimate based on five analysts.
- Net New Orders in Units - Total: 6,214 versus 5,838 estimated by five analysts on average.
- Active Communities: 919 versus the five-analyst average estimate of 916.
- Closings (units) - Total: 7,615 versus 8,017 estimated by five analysts on average.
- Unit Backlog - Total: 12,146 compared to the 11,368 average estimate based on five analysts.
- Backlog Value - Total: $7.32 billion compared to the $7.21 billion average estimate based on two analysts.
- Net New Orders (Value) - Total: $3.36 billion compared to the $3.46 billion average estimate based on two analysts.
- Homebuilding- Home sale revenues: $4.17 billion compared to the $4.37 billion average estimate based on seven analysts. The reported number represents a change of -17.6% year over year.
- Revenues- Financial Services: $93.88 million compared to the $75.91 million average estimate based on seven analysts. The reported number represents a change of +30.2% year over year.
- Revenues- Homebuilding: $4.20 billion compared to the $4.41 billion average estimate based on seven analysts. The reported number represents a change of -17.6% year over year.
- Homebuilding- Land sale revenues: $34.54 million compared to the $37.16 million average estimate based on six analysts. The reported number represents a change of -24.1% year over year.
- Income / (loss) before income taxes- Homebuilding: $902.97 million compared to the $905.63 million average estimate based on three analysts.
Shares of PulteGroup have returned +2.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217862/pultegroup-phm-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:45:20Z
|
blocked_url
|
Commvault Systems (CVLT - Free Report) reported $216.81 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 11.1%. EPS of $0.78 for the same period compares to $0.62 a year ago.
The reported revenue represents a surprise of +4.08% over the Zacks Consensus Estimate of $208.3 million. With the consensus EPS estimate being $0.73, the EPS surprise was +6.85%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Commvault performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Annualized Recurring Revenue (ARR): $752.48 compared to the $731.79 average estimate based on two analysts.
- Revenues- Perpetual license: $14.87 million versus the three-analyst average estimate of $12.64 million. The reported number represents a year-over-year change of -24.6%.
- Revenues- Other services: $10.88 million versus the three-analyst average estimate of $11.06 million.
- Revenues- Customer support: $76.81 million versus $76.39 million estimated by three analysts on average.
- Revenues- Subscription: $114.25 million versus $108.17 million estimated by three analysts on average.
Shares of Commvault have returned +2.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217863/commvault-cvlt-reports-q3-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:45:26Z
|
blocked_url
|
For the quarter ended December 2023, Danaher (DHR - Free Report) reported revenue of $6.41 billion, down 23.5% over the same period last year. EPS came in at $2.09, compared to $2.87 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.99 billion, representing a surprise of +6.93%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $1.90.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total Growth - Organic sales (Core): -4.5% versus -19.5% estimated by five analysts on average.
- Total sales- Diagnostics: $2.72 billion compared to the $2.39 billion average estimate based on five analysts. The reported number represents a change of -8.4% year over year.
- Total sales- Life Sciences: $1.93 billion versus $1.85 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.8% change.
- Total sales- Biotechnology: $1.76 billion compared to the $1.68 billion average estimate based on five analysts.
- Operating profit- Life Sciences: $235 million compared to the $347.24 million average estimate based on three analysts.
- Operating profit- Biotechnology: $416 million versus $465.82 million estimated by three analysts on average.
- Operating profit- Other: -$80 million compared to the -$73.68 million average estimate based on three analysts.
- Operating profit- Diagnostics: $766 million versus the three-analyst average estimate of $573.35 million.
Shares of Danaher have returned +1.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217864/danaher-dhr-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-30T23:45:32Z
|
blocked_url
|
For the quarter ended December 2023, Corning (GLW - Free Report) reported revenue of $3.27 billion, down 9.9% over the same period last year. EPS came in at $0.39, compared to $0.47 in the year-ago quarter.
The reported revenue represents a surprise of +0.49% over the Zacks Consensus Estimate of $3.26 billion. With the consensus EPS estimate being $0.40, the EPS surprise was -2.50%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Corning performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Display Technologies: $869 million versus the five-analyst average estimate of $843.29 million. The reported number represents a year-over-year change of +11%.
- Net Sales- Optical Communications: $903 million compared to the $837.50 million average estimate based on five analysts. The reported number represents a change of -24.4% year over year.
- Net Sales- Environmental Technologies: $429 million compared to the $418.80 million average estimate based on five analysts. The reported number represents a change of +8.9% year over year.
- Net Sales- Specialty Materials: $473 million compared to the $522.49 million average estimate based on five analysts. The reported number represents a change of -6.3% year over year.
- Net Sales- Life Sciences: $242 million versus $221.90 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -17.7% change.
- Net Sales- Hemlock and Emerging Growth Businesses: $356 million compared to the $358.20 million average estimate based on four analysts. The reported number represents a change of -22.9% year over year.
- Segment Net Income- Optical Communications: $88 million versus the three-analyst average estimate of $92.59 million.
- Segment Net Income- Display Technologies: $232 million compared to the $225.41 million average estimate based on three analysts.
- Segment Net Income- Life Sciences: $17 million compared to the $11.05 million average estimate based on three analysts.
- Segment Net Income- Environmental Technologies: $98 million versus the three-analyst average estimate of $82.93 million.
- Segment Net Income- Specialty Materials: $58 million versus $71.52 million estimated by three analysts on average.
- Segment Net Income- Hemlock and Emerging Growth Businesses: -$19 million compared to the -$2.05 million average estimate based on two analysts.
Shares of Corning have returned +2.3% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217865/corning-glw-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-30T23:45:38Z
|
blocked_url
|
For the quarter ended December 2023, Hope Bancorp (HOPE - Free Report) reported revenue of $135.2 million, down 16.9% over the same period last year. EPS came in at $0.32, compared to $0.43 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $139.6 million, representing a surprise of -3.16%. The company delivered an EPS surprise of +14.29%, with the consensus EPS estimate being $0.28.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Hope Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Interest Margin: 2.7% compared to the 2.8% average estimate based on three analysts.
- Average Balance - Total interest earning assets: $18.53 billion versus the two-analyst average estimate of $18.96 billion.
- Net charge-offs to average loans: 0.1% versus the two-analyst average estimate of 0.2%.
- Net Interest Income: $125.92 million versus the three-analyst average estimate of $130.44 million.
- Total noninterest income: $9.28 million versus $8.81 million estimated by three analysts on average.
- Service fees on deposit accounts: $2.51 million compared to the $2.22 million average estimate based on two analysts.
Shares of Hope Bancorp have returned -1.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217866/hope-bancorp-hope-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:45:44Z
|
blocked_url
|
Oshkosh (OSK - Free Report) reported $2.47 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 11.9%. EPS of $2.56 for the same period compares to $1.60 a year ago.
The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $2.47 billion. With the consensus EPS estimate being $2.17, the EPS surprise was +17.97%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Oshkosh performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Defense: $586.90 million compared to the $592.08 million average estimate based on four analysts. The reported number represents a change of +7.2% year over year.
- Net Sales- Access- Other: $255.70 million versus $231.84 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.5% change.
- Net Sales- Access- Aerial work platforms: $540.40 million compared to the $607.01 million average estimate based on four analysts. The reported number represents a change of -0.1% year over year.
- Net Sales- Corporate and intersegment eliminations: -$5.70 million versus the four-analyst average estimate of -$2.20 million. The reported number represents a year-over-year change of +470%.
- Net Sales- Access- Telehandlers: $354.20 million versus $345.22 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
- Net Sales- Access- Total: $1.15 billion versus the four-analyst average estimate of $1.18 billion. The reported number represents a year-over-year change of +7.1%.
- Net sales- Vocational- Fire apparatus: $302.20 million versus the three-analyst average estimate of $292.39 million.
- Net sales- Vocational- Total: $735.30 million compared to the $672.44 million average estimate based on three analysts.
- Net sales- Vocational- Other: $291.40 million versus the two-analyst average estimate of $192.06 million.
- Net sales- Vocational- Refuse collection: $141.70 million versus the two-analyst average estimate of $156.07 million.
- Operating income (loss)- Corporate and intersegment eliminations: -$52 million compared to the -$55.54 million average estimate based on four analysts.
- Operating income (loss)- Access: $162.20 million versus $172.42 million estimated by three analysts on average.
Shares of Oshkosh have returned +4.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217867/compared-to-estimates-oshkosh-osk-q4-earnings-a-look-at-key-metrics
| 2024-01-30T23:45:51Z
|
blocked_url
|
JetBlue Airways (JBLU - Free Report) reported $2.33 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 3.7%. EPS of -$0.19 for the same period compares to $0.22 a year ago.
The reported revenue represents a surprise of +1.43% over the Zacks Consensus Estimate of $2.29 billion. With the consensus EPS estimate being -$0.28, the EPS surprise was +32.14%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how JetBlue performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Load factor: 80.1% compared to the 82.5% average estimate based on four analysts.
- Average fuel cost per gallon, including fuel taxes: $3.08 versus $3.07 estimated by three analysts on average.
- Yield per passenger mile: 15.89 cents compared to the 15.3 cents average estimate based on three analysts.
- Operating revenue per ASM: 13.67 cents versus the three-analyst average estimate of 13.58 cents.
- Available seat miles (ASMs): 17,013 million versus 16,889.15 million estimated by three analysts on average.
- Operating expense per ASM, excluding fuel: 9.82 cents versus the three-analyst average estimate of 10.05 cents.
- Revenue passenger miles (RPMs): 13,628 million versus the three-analyst average estimate of 13,964.94 million.
- Passenger revenue per ASM: 12.73 cents compared to the 12.63 cents average estimate based on three analysts.
- Fuel gallons consumed: 220 Mgal versus the two-analyst average estimate of 227.73 Mgal.
- Operating expense per ASM: 14.06 cents versus the two-analyst average estimate of 14.35 cents.
- Operating Revenues- Passenger: $2.17 billion compared to the $2.13 billion average estimate based on four analysts. The reported number represents a change of -4.5% year over year.
- Operating Revenues- Other: $159 million versus $158.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.4% change.
Shares of JetBlue have returned -0.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217868/heres-what-key-metrics-tell-us-about-jetblue-jblu-q4-earnings
| 2024-01-30T23:45:57Z
|
blocked_url
|
A.O. Smith (AOS - Free Report) reported $988.1 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 5.6%. EPS of $0.97 for the same period compares to $0.86 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $989.08 million, representing a surprise of -0.10%. The company delivered an EPS surprise of +1.04%, with the consensus EPS estimate being $0.96.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how A.O. Smith performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- North America: $738 million versus $738.08 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +6.7% change.
- Geographic Revenue- Inter-segment sales: -$10.10 million compared to the -$6.13 million average estimate based on seven analysts. The reported number represents a change of +80.4% year over year.
- Geographic Revenue- Rest of World: $260.20 million compared to the $256.49 million average estimate based on seven analysts. The reported number represents a change of +4.2% year over year.
- Segment Operating Earnings (GAAP)- Corporate expense: -$17.10 million versus -$13.52 million estimated by six analysts on average.
Shares of A.O. Smith have returned -1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217869/ao-smith-aos-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-30T23:46:03Z
|
blocked_url
|
Polaris Inc (PII - Free Report) reported $2.29 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 4.8%. EPS of $1.98 for the same period compares to $3.46 a year ago.
The reported revenue represents a surprise of +1.59% over the Zacks Consensus Estimate of $2.25 billion. With the consensus EPS estimate being $2.67, the EPS surprise was -25.84%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Polaris Inc performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Marine: $143.20 million compared to the $136.07 million average estimate based on four analysts.
- Sales- On-Road: $229.20 million versus the four-analyst average estimate of $208.62 million.
- Sales- Off-Road: $1.92 billion compared to the $1.92 billion average estimate based on four analysts.
- Gross profit- Marine: $25.70 million versus the three-analyst average estimate of $23.84 million.
- Gross profit- Off-Road: $409 million versus the three-analyst average estimate of $434.15 million.
- Gross profit- On-Road: $31.70 million compared to the $40.22 million average estimate based on three analysts.
Shares of Polaris Inc have returned -2.2% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217870/compared-to-estimates-polaris-inc-pii-q4-earnings-a-look-at-key-metrics
| 2024-01-30T23:46:09Z
|
blocked_url
|
For the quarter ended December 2023, ManpowerGroup (MAN - Free Report) reported revenue of $4.63 billion, down 3.7% over the same period last year. EPS came in at $1.45, compared to $2.08 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $4.56 billion, representing a surprise of +1.51%. The company delivered an EPS surprise of +19.83%, with the consensus EPS estimate being $1.21.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Manpower performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues from Services- Americas- Other Americas: $372.30 million versus the three-analyst average estimate of $363.90 million. The reported number represents a year-over-year change of +2.7%.
- Revenues from Services- Southern Europe: $2.11 billion versus $2.03 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.5% change.
- Revenues from Services- Americas- United States: $702.30 million versus $718.49 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.3% change.
- Revenues from Services- Southern Europe- France: $1.21 billion versus the three-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of +1.2%.
- Revenues from Services- Northern Europe: $913.70 million compared to the $916.64 million average estimate based on three analysts. The reported number represents a change of -6.1% year over year.
- Revenues from Services- Southern Europe- Other Southern Europe: $487 million compared to the $459.07 million average estimate based on three analysts. The reported number represents a change of -1.4% year over year.
- Revenues from Services- APME: $552.20 million versus the three-analyst average estimate of $536.91 million. The reported number represents a year-over-year change of -4.6%.
- Revenues from Services- Americas: $1.07 billion versus $1.08 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -9.1% change.
- Revenues from Services- Southern Europe- Italy: $415.10 million versus the three-analyst average estimate of $404.60 million. The reported number represents a year-over-year change of +0.6%.
Shares of Manpower have returned -3.7% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217871/heres-what-key-metrics-tell-us-about-manpower-man-q4-earnings
| 2024-01-30T23:46:16Z
|
blocked_url
|
For the quarter ended December 2023, Cambridge (CATC - Free Report) reported revenue of $38.53 million, down 24.4% over the same period last year. EPS came in at $1.11, compared to $1.92 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $37.7 million, representing a surprise of +2.20%. The company delivered an EPS surprise of +20.65%, with the consensus EPS estimate being $0.92.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Cambridge performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Efficiency Ratio: 69.7% versus the two-analyst average estimate of 72%.
- Net Interest Margin, FTE (GAAP): 2.1% versus 2.1% estimated by two analysts on average.
- Total Noninterest Income: $10.44 million versus $10.44 million estimated by two analysts on average.
- Net interest income on a fully taxable equivalent basis (GAAP): $28.09 million versus the two-analyst average estimate of $27.38 million.
Shares of Cambridge have returned +4.2% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217872/cambridge-catc-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:46:22Z
|
blocked_url
|
For the quarter ended December 2023, United Parcel Service (UPS - Free Report) reported revenue of $24.92 billion, down 7.8% over the same period last year. EPS came in at $2.47, compared to $3.62 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $25.31 billion, representing a surprise of -1.54%. The company delivered an EPS surprise of +1.23%, with the consensus EPS estimate being $2.44.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how UPS performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Average revenue per piece - International Package - Total: $20.68 versus the four-analyst average estimate of $20.27.
- Average daily package volume - International Package - Export: 1,771 thousand versus 1,796.83 thousand estimated by four analysts on average.
- Average daily package volume - International Package - Domestic: 1,653 thousand versus 1,727.06 thousand estimated by four analysts on average.
- Average revenue per piece - U.S. Domestic Package - Ground: $10.62 versus the four-analyst average estimate of $10.87.
- Revenue- Supply Chain Solutions: $3.40 billion compared to the $3.37 billion average estimate based on six analysts. The reported number represents a change of -11.4% year over year.
- Revenue- International Package: $4.61 billion compared to the $4.66 billion average estimate based on six analysts. The reported number represents a change of -7% year over year.
- Revenue- U.S. Domestic Package: $16.92 billion versus the six-analyst average estimate of $17.23 billion. The reported number represents a year-over-year change of -7.3%.
- Revenue- International Package- Cargo and other: $145 million versus $182.42 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -36.7% change.
- Revenue- U.S. Domestic Package- Ground: $12.66 billion versus the five-analyst average estimate of $12.98 billion. The reported number represents a year-over-year change of -7.1%.
- Revenue- U.S. Domestic Package- Next Day Air: $2.65 billion versus $2.60 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -4.4% change.
- Revenue- International Package- Domestic: $845 million versus the five-analyst average estimate of $841.11 million. The reported number represents a year-over-year change of -4.1%.
- Revenue- International Package- Export: $3.62 billion versus $3.65 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.8% change.
Shares of UPS have returned +0.5% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217873/ups-ups-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-30T23:46:28Z
|
blocked_url
|
For the quarter ended December 2023, Sysco (SYY - Free Report) reported revenue of $19.29 billion, up 3.7% over the same period last year. EPS came in at $0.89, compared to $0.80 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $19.3 billion, representing a surprise of -0.04%. The company delivered an EPS surprise of +1.14%, with the consensus EPS estimate being $0.88.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sysco performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- International Foodservice Operations: $3.60 billion versus the two-analyst average estimate of $3.65 billion. The reported number represents a year-over-year change of +9.6%.
- U.S. Foodservice Operations: $13.49 billion versus $13.38 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.2% change.
- Sales- Other: $283.33 million versus $301.84 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.9% change.
- Sales- SYGMA: $1.91 billion versus the two-analyst average estimate of $1.93 billion. The reported number represents a year-over-year change of -1%.
- Operating income (GAAP)- Other: $8.39 million compared to the $10.14 million average estimate based on two analysts.
- Operating income (GAAP)- SYGMA: $16.35 million compared to the $9.93 million average estimate based on two analysts.
- OTHER- Gross Profit: $73.01 million versus the two-analyst average estimate of $77.77 million.
- SYGMA- Gross Profit: $148.51 million versus $150.62 million estimated by two analysts on average.
Shares of Sysco have returned +2.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217874/compared-to-estimates-sysco-syy-q2-earnings-a-look-at-key-metrics
| 2024-01-30T23:46:34Z
|
blocked_url
|
For the quarter ended December 2023, Marathon Petroleum (MPC - Free Report) reported revenue of $36.82 billion, down 8.2% over the same period last year. EPS came in at $3.98, compared to $6.65 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $33.73 billion, representing a surprise of +9.18%. The company delivered an EPS surprise of +68.64%, with the consensus EPS estimate being $2.36.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Marathon Petroleum performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Refining & Marketing - Net refinery throughput: 2931 millions of barrels of oil per day versus the four-analyst average estimate of 2891.22 millions of barrels of oil per day.
- Refining & Marketing - Crude oil refined Throughput: 2668 millions of barrels of oil per day versus 2627.38 millions of barrels of oil per day estimated by three analysts on average.
- Income from operations- Refining & Marketing: $1.24 billion versus $811.90 million estimated by four analysts on average.
- Income from operations- Midstream: $1.29 billion versus the four-analyst average estimate of $1.19 billion.
- Corporate and other unallocated items: -$224 million compared to the -$458.21 million average estimate based on three analysts.
- Midstream Segment- Segment EBITDA: $1.57 billion compared to the $1.45 billion average estimate based on three analysts.
- Refining & Marketing- EBITDA: $2.16 billion versus the two-analyst average estimate of $1.48 billion.
Shares of Marathon Petroleum have returned +7.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217875/marathon-petroleum-mpc-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:46:41Z
|
blocked_url
|
Pentair plc (PNR - Free Report) reported $984.6 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 1.8%. EPS of $0.87 for the same period compares to $0.82 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $972.85 million, representing a surprise of +1.21%. The company delivered an EPS surprise of +1.16%, with the consensus EPS estimate being $0.86.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Pentair plc performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Pool: $336.20 million versus $325.39 million estimated by seven analysts on average.
- Net Sales- Industrial & Flow Technologies: $378.50 million versus $373.51 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change.
- Net Sales- Water Solutions: $269.60 million versus $272.09 million estimated by seven analysts on average.
- Net Sales- Other: $0.30 million versus $0.27 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Segment income (loss)- Other: -$23.90 million versus -$22.02 million estimated by seven analysts on average.
- Segment income (loss)- Pool: $105.10 million versus $97.20 million estimated by seven analysts on average.
- Segment income (loss)- Water Solutions: $51.60 million versus the seven-analyst average estimate of $53.56 million.
- Segment income (loss)- Industrial & Flow Technologies: $65 million versus the seven-analyst average estimate of $67.73 million.
Shares of Pentair plc have returned +0.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217876/pentair-plc-pnr-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-30T23:46:47Z
|
blocked_url
|
Lam Research (LRCX - Free Report) reported $3.76 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 28.8%. EPS of $7.52 for the same period compares to $10.71 a year ago.
The reported revenue represents a surprise of +1.30% over the Zacks Consensus Estimate of $3.71 billion. With the consensus EPS estimate being $7.06, the EPS surprise was +6.52%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Lam Research performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Leading- and non-leading-edge equipment and upgrade Revenue - Memory: 48% versus 39.1% estimated by two analysts on average.
- Leading- and non-leading-edge equipment and upgrade Revenue - Logic/integrated device manufacturing: 14% versus 26.1% estimated by two analysts on average.
- Leading- and non-leading-edge equipment and upgrade Revenue - Foundry: 38% versus 34.8% estimated by two analysts on average.
- Revenue- Customer support-related revenue and other: $1.46 billion compared to the $1.44 billion average estimate based on three analysts. The reported number represents a change of -15.7% year over year.
- Revenue- Systems: $2.30 billion versus $2.27 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -35.2% change.
Shares of Lam Research have returned +8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217877/lam-research-lrcx-reports-q2-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:46:53Z
|
blocked_url
|
Johnson Controls (JCI - Free Report) reported $6.09 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.4%. EPS of $0.51 for the same period compares to $0.67 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $6.13 billion, representing a surprise of -0.52%. The company delivered an EPS surprise of +2.00%, with the consensus EPS estimate being $0.50.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Johnson Controls performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Building Solutions North America: $2.49 billion versus the three-analyst average estimate of $2.52 billion. The reported number represents a year-over-year change of +5.1%.
- Net Sales- Building Solutions EMEA/LA: $1.04 billion compared to the $1.03 billion average estimate based on three analysts. The reported number represents a change of +6.5% year over year.
- Net Sales- Building Solutions Asia Pacific: $507 million versus the three-analyst average estimate of $613.18 million. The reported number represents a year-over-year change of -21.5%.
- Net Sales- Global Products: $2.06 billion versus the three-analyst average estimate of $2.01 billion. The reported number represents a year-over-year change of -0.9%.
- Total Segment Adjusted EBITA- Global Products: $369 million versus $395.44 million estimated by two analysts on average.
Shares of Johnson Controls have returned -1.7% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217878/compared-to-estimates-johnson-controls-jci-q1-earnings-a-look-at-key-metrics
| 2024-01-30T23:46:59Z
|
blocked_url
|
For the quarter ended December 2023, HCA Healthcare (HCA - Free Report) reported revenue of $17.3 billion, up 11.7% over the same period last year. EPS came in at $5.90, compared to $4.64 in the year-ago quarter.
The reported revenue represents a surprise of +4.52% over the Zacks Consensus Estimate of $16.55 billion. With the consensus EPS estimate being $5.05, the EPS surprise was +16.83%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue per Equivalent Admission: $17,755 versus $17,197.66 estimated by four analysts on average.
- Equivalent Admissions: 974.56 million versus 966.53 million estimated by four analysts on average.
- Number of hospitals: 186 compared to the 183 average estimate based on three analysts.
- Equivalent Patient Days: 4,786.2 thousand versus 4,717.14 thousand estimated by three analysts on average.
- Admissions: 544.55 million versus 543.26 million estimated by two analysts on average.
- Average Length of Stay: 5 compared to the 5 average estimate based on two analysts.
- Licensed Beds at End of Period: 49,588 versus 49,292 estimated by two analysts on average.
- Same Facility - Equivalent Admissions: 959.37 thousand versus the two-analyst average estimate of 960.06 thousand.
- Same Facility - Revenue per Equivalent Admission: $17,672 versus the two-analyst average estimate of $16,702.68.
- Patient Days: 2,674.33 Days versus the two-analyst average estimate of 2,613.57 Days.
- Number of freestanding outpatient surgery centers: 124 versus the two-analyst average estimate of 126.
Shares of HCA have returned +5.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2217879/hca-hca-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-30T23:47:05Z
|
blocked_url
|
For the quarter ended December 2023, General Motors Company (GM - Free Report) reported revenue of $42.98 billion, down 0.3% over the same period last year. EPS came in at $1.24, compared to $2.12 in the year-ago quarter.
The reported revenue represents a surprise of +5.40% over the Zacks Consensus Estimate of $40.78 billion. With the consensus EPS estimate being $1.12, the EPS surprise was +10.71%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how General Motors Company performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Worldwide - Wholesale Vehicle Sales - Total GMNA: 782 thousand compared to the 706.03 thousand average estimate based on three analysts.
- Worldwide - Wholesale Vehicle Sales - Total: 943 thousand versus the two-analyst average estimate of 913.6 thousand.
- Worldwide - Wholesale Vehicle Sales - Total GMI: 161 thousand compared to the 216.58 thousand average estimate based on two analysts.
- Total net sales and revenue- GM Financial: $3.74 billion compared to the $3.21 billion average estimate based on four analysts. The reported number represents a change of +14.2% year over year.
- Total net sales and revenue- Total Automotive-GMI: $3.94 billion compared to the $5.12 billion average estimate based on three analysts. The reported number represents a change of -8.8% year over year.
- Total net sales and revenue- Total Automotive-GMNA: $35.23 billion versus $31.24 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.7% change.
- Total net sales and revenue- Total Automotive: $39.26 billion versus the three-analyst average estimate of $36.80 billion. The reported number represents a year-over-year change of -1.4%.
- Total net sales and revenue- Total Automotive-Corporate: $96 million versus the two-analyst average estimate of $38.24 million. The reported number represents a year-over-year change of +118.2%.
- Total net sales and revenue- GM Cruise: $25 million versus the two-analyst average estimate of $25.01 million. The reported number represents a year-over-year change of 0%.
- Total net sales and revenue- Eliminations: -$53 million versus -$26.40 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +89.3% change.
- Operating segments- GM Cruise: -$792 million compared to the -$661.79 million average estimate based on three analysts.
- Operating segments- GMNA: $2.01 billion versus $2.06 billion estimated by three analysts on average.
Shares of General Motors Company have returned -1.5% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2217880/general-motors-company-gm-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-30T23:47:12Z
|
blocked_url
|
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Let's take a look at what these Wall Street heavyweights have to say about Palo Alto Networks (PANW - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Palo Alto currently has an average brokerage recommendation (ABR) of 1.39, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 41 brokerage firms. An ABR of 1.39 approximates between Strong Buy and Buy.
Of the 41 recommendations that derive the current ABR, 32 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 78.1% and 4.9% of all recommendations.
Brokerage Recommendation Trends for PANW
Check price target & stock forecast for Palo Alto here>>>
While the ABR calls for buying Palo Alto, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is PANW a Good Investment?
Looking at the earnings estimate revisions for Palo Alto, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.49.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Palo Alto. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Palo Alto.
|
https://www.zacks.com/stock/news/2217882/is-palo-alto-panw-a-buy-as-wall-street-analysts-look-optimistic?
| 2024-01-30T23:47:18Z
|
blocked_url
|
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have to say about Eli Lilly (LLY - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Lilly currently has an average brokerage recommendation (ABR) of 1.21, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 21 brokerage firms. An ABR of 1.21 approximates between Strong Buy and Buy.
Of the 21 recommendations that derive the current ABR, 18 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.7% and 4.8% of all recommendations.
Brokerage Recommendation Trends for LLY
Check price target & stock forecast for Lilly here>>>
While the ABR calls for buying Lilly, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is LLY a Good Investment?
Looking at the earnings estimate revisions for Lilly, the Zacks Consensus Estimate for the current year has declined 0.4% over the past month to $6.61.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Lilly. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Lilly with a grain of salt.
|
https://www.zacks.com/stock/news/2217883/is-lilly-lly-a-buy-as-wall-street-analysts-look-optimistic?
| 2024-01-30T23:47:24Z
|
blocked_url
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Byd Co., Ltd. (BYDDY - Free Report) .
Byd Co., Ltd. currently has an average brokerage recommendation (ABR) of 1.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by five brokerage firms. An ABR of 1.00 indicates Strong Buy.
Of the five recommendations that derive the current ABR, five are Strong Buy, representing 100% of all recommendations.
Brokerage Recommendation Trends for BYDDY
Check price target & stock forecast for Byd Co., Ltd. here>>>
While the ABR calls for buying Byd Co., Ltd., it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is BYDDY a Good Investment?
Looking at the earnings estimate revisions for Byd Co., Ltd., the Zacks Consensus Estimate for the current year has increased 8.6% over the past month to $2.90.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Byd Co., Ltd. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Byd Co., Ltd. may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2217884/wall-street-analysts-see-byd-co-ltd-byddy-as-a-buy-should-you-invest?
| 2024-01-30T23:47:30Z
|
blocked_url
|
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Let's take a look at what these Wall Street heavyweights have to say about Novo Nordisk (NVO - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Novo Nordisk currently has an average brokerage recommendation (ABR) of 1.58, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 13 brokerage firms. An ABR of 1.58 approximates between Strong Buy and Buy.
Of the 13 recommendations that derive the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 69.2% and 7.7% of all recommendations.
Brokerage Recommendation Trends for NVO
Check price target & stock forecast for Novo Nordisk here>>>
While the ABR calls for buying Novo Nordisk, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is NVO Worth Investing In?
Looking at the earnings estimate revisions for Novo Nordisk, the Zacks Consensus Estimate for the current year has increased 3.1% over the past month to $2.67.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Novo Nordisk. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Novo Nordisk may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2217885/wall-street-analysts-see-novo-nordisk-nvo-as-a-buy-should-you-invest?
| 2024-01-30T23:47:37Z
|
blocked_url
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Micron (MU - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Micron currently has an average brokerage recommendation (ABR) of 1.32, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 27 brokerage firms. An ABR of 1.32 approximates between Strong Buy and Buy.
Of the 27 recommendations that derive the current ABR, 22 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 81.5% and 7.4% of all recommendations.
Brokerage Recommendation Trends for MU
Check price target & stock forecast for Micron here>>>
The ABR suggests buying Micron, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is MU a Good Investment?
In terms of earnings estimate revisions for Micron, the Zacks Consensus Estimate for the current year has increased 1.1% over the past month to -$0.43.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Micron. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Micron may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2217886/micron-mu-is-considered-a-good-investment-by-brokers-is-that-true?
| 2024-01-30T23:47:43Z
|
blocked_url
|
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium service makes this easier. It features daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All of these can help you quickly identify what stocks to buy, what to sell, and what are today's hottest industries.
It also includes the Focus List, a long-term portfolio of top stocks that have all the elements to beat the market.
Breaking Down the Zacks Focus List
If you could, wouldn't you jump at the chance for access to a curated list of stocks to kickstart your investing journey?
That's what the Zacks Focus List offers. It's a portfolio of 50 stocks that serve as a starting point for long-term investors to build their individual portfolios. The stocks included in the list are set to outperform the market over the next 12 months.
What makes the Focus List even more helpful is that each selection is accompanied by a full Zacks Analyst Report, which explains the reasoning behind every stock's selection and why we believe it's a good pick for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List Methodology
When stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Brokerage analysts are in charge of determining a company's growth and profitability expectations, or earnings estimates. These analysts work together with company management to evaluate all factors that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
Earnings estimate revisions are very important, since investors also need to take into consideration what a company will earn in the future.
The stocks that receive positive changes to earnings estimates are more likely to receive even more upward changes in the future. Take this example: if an analyst raised their estimates last month, they'll probably do so again this month, and other analysts will follow.
Harnessing the power of earnings estimate revisions is where the Zacks Rank comes in. The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions to make it easier to build a winning portfolio.
The Zacks Rank consists of four main pillars: Agreement, Magnitude, Upside, and Surprise. Each one is given a raw score, which is recalculated every night and compiled into the Rank. Then, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell," using this data.
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
Since stock prices respond to revisions, it can be very profitable to buy stocks with rising earnings estimates. By buying Focus List stocks, then, you're likely getting into companies whose future earnings estimates will be raised, potentially leading to price momentum.
Focus List Spotlight: Visa (V - Free Report)
Incorporated in 2007 as a Delaware stock corporation and headquartered in San Francisco, CA, Visa Inc. operates as a payments technology company all over the world. The company went public in March 2008 via an initial public offering (IPO). It was founded in 1958. The company has evolved and grown over the course of the last six decades
Since being added to the Focus List on May 30, 2017 at $94.67 per share, shares of V have increased 189.07% to $273.66. The stock is currently a #3 (Hold) on the Zacks Rank.
For fiscal 2024, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $9.91. V boasts an average earnings surprise of 4.1%.
Moreover, analysts are expecting V's earnings to grow 13% for the current fiscal year.
Reveal Winning Stocks
Unlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
|
https://www.zacks.com/stock/news/2217887/earnings-growth-price-strength-make-visa-v-a-stock-to-watch?-price-strength-make-visa-(v)-a-stock-to-watch
| 2024-01-30T23:47:49Z
|
blocked_url
|
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.
It also includes the Focus List, a long-term portfolio of top stocks that have all the elements to beat the market.
Breaking Down the Zacks Focus List
If you could, wouldn't you jump at the chance for access to a curated list of stocks to kickstart your investing journey?
That's what the Zacks Focus List offers. It's a portfolio of 50 stocks that serve as a starting point for long-term investors to build their individual portfolios. The stocks included in the list are set to outperform the market over the next 12 months.
One thing that makes the Focus List even more advantageous is that each pick comes with a full Zacks Analyst Report. This helps explain why each stock was selected and why we believe it's a good pick for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List Methodology
When stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Earnings estimates, or expectations of growth and profitability, come from brokerage analysts who track publicly traded companies; these analysts work together with company management to analyze every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
What a company will earn down the road also needs to be taken into consideration, and this is why earnings estimate revisions are so important.
Stocks that receive upward earnings estimate revisions are more likely to receive even more upward changes in the future. For example, if an analyst raised their estimates last month, they're more likely to do it again this month, and other analysts are likely to do the same.
Harnessing the power of earnings estimate revisions is where the Zacks Rank comes in. The Zacks Rank is a unique, proprietary stock-rating model that utilizes changes to a company's quarterly earnings expectations to help investors build a winning portfolio.
The Zacks Rank consists of four main pillars: Agreement, Magnitude, Upside, and Surprise. Each one is given a raw score, which is recalculated every night and compiled into the Rank. Then, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell," using this data.
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
Because stock prices react to revisions, buying stocks with rising earnings estimates can be very profitable. Focus List stocks offer investors a great opportunity to get into companies whose future earnings estimates will be raised, potentially leading to price momentum.
Focus List Spotlight: Microsoft (MSFT - Free Report)
Microsoft Corporation is one of the largest broad-based technology providers in the world. The company dominates the PC software market with more than 73% of the market share for desktop operating systems.
MSFT, a #3 (Hold) stock, was added to the Focus List on February 1, 2016 at $55.09 per share. Since then, shares have increased 643.73% to $409.72.
Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.02 to $11.15. MSFT boasts an average earnings surprise of 7.8%.
Additionally, MSFT's earnings are expected to grow 13.7% for the current fiscal year.
Reveal Winning Stocks
Unlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
|
https://www.zacks.com/stock/news/2217888/new-to-investing-this-1-computer-and-technology-stock-could-be-the-perfect-starting-point?-this-1-computer-and-technology-stock-could-be-the-perfect-starting-point
| 2024-01-30T23:47:56Z
|
blocked_url
|
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium service, which provides daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter, makes these more manageable goals. All of the features can help you identify what stocks to buy, what to sell, and what are today's hottest industries.
It also includes the Focus List, a long-term portfolio of top stocks that have all the elements to beat the market.
Breaking Down the Zacks Focus List
Building an investment portfolio from scratch can be difficult, so if you could, wouldn't you take a peek at a curated list of top stocks?
Enter the Zacks Focus List. It's a portfolio made up of 50 stocks that are set to beat the market over the next 12 months; each company selected serves as a foundation for long-term investors looking to create an individual portfolio.
One thing that makes the Focus List even more advantageous is that each pick comes with a full Zacks Analyst Report. This helps explain why each stock was selected and why we believe it's a good pick for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List Methodology
When stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Earnings estimates are expectations of growth and profitability, and are determined by brokerage analysts. Together with company management, these analysts examine every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
What a company will earn down the road also needs to be taken into consideration, and this is why earnings estimate revisions are so important.
The stocks that receive positive changes to earnings estimates are more likely to receive even more upward changes in the future. Take this example: if an analyst raised their estimates last month, they'll probably do so again this month, and other analysts will follow.
Utilizing the power of earnings estimate revisions is when the Zacks Rank joins the party. A unique, proprietary stock-rating model, the Zacks Rank uses changes to quarterly earnings expectations to help investors create a winning portfolio.
The Zacks Rank consists of four main pillars: Agreement, Magnitude, Upside, and Surprise. Each one is given a raw score, which is recalculated every night and compiled into the Rank. Then, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell," using this data.
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
Since stock prices respond to revisions, it can be very profitable to buy stocks with rising earnings estimates. By buying Focus List stocks, then, you're likely getting into companies whose future earnings estimates will be raised, potentially leading to price momentum.
Focus List Spotlight: Ulta Beauty (ULTA - Free Report)
Bolingbrook, IL-based, Ulta Beauty Inc., previously known as Ulta Salon, Cosmetics & Fragrance, Inc., is a leading beauty retailer in the United States. Founded in 1990, the company changed its name to Ulta Beauty in January 2017.
On March 25, 2020, ULTA was added to the Focus List at $177.59 per share. Shares have increased 186.05% to $507.99 since then, and the company is a #3 (Hold) on the Zacks Rank.
Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.07 to $25.52. ULTA also boasts an average earnings surprise of 5.8%.
Moreover, analysts are expecting ULTA's earnings to grow 6.3% for the current fiscal year.
Reveal Winning Stocks
Unlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
|
https://www.zacks.com/stock/news/2217889/why-ulta-beauty-ulta-is-a-top-stock-for-the-long-term
| 2024-01-30T23:48:02Z
|
blocked_url
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.